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ABSTRACT 
Adequate treatment of tuberculosis (TB) is important both to cure the patient and 
to decrease airborne transmission of this infectious disease. The most common way 
to evaluate the quality of tuberculosis treatment is by presenting treatment outcomes. 
Outcomes reflect treatment efficacy in a shorter period; thus, more permanent cures 
can be assessed by evaluating TB recurrence. It is important to distinguish the two 
ways of recurrences, relapses and re-infections when evaluating the quality of TB 
treatment, because only relapses reflect shortcomings in the treatment of the 
previous TB episode.   
The aim of this thesis was to evaluate the quality of tuberculosis treatment in 
Finland by assessing treatment outcomes at one year and recurrence of tuberculosis 
in a longer period and to determine risk factors for non-successful treatment. This 
study additionally aimed to distinguish relapses from re-infections among recurrent 
cases and to evaluate the validity of treatment outcomes notified and the adequacy 
of TB treatments prescribed in the episodes preceding recurrence. 
This retrospective cohort study is based on TB cases registered in the National 
Infectious Disease register. Treatment outcomes were evaluated for 1416 
microbiologically confirmed pulmonary TB cases, excluding cases with multi-drug 
resistant strains, in a study period of eight years. TB recurrence was evaluated among 
the cohort of 8084 TB cases in a study period of 19 years. Relapses were 
distinguished from re-infections among recurrent cases when the isolates of the 
causing bacteria, Mycobacterium tuberculosis, were available for genotyping from both 
TB episodes. A novel genotyping method, whole genome sequencing, was used in 
this study.  
The treatment outcome was notified as successful in 75% of cases. Death as 
outcome was common with 16% proportion, whereas the other most unsuccessful 
outcomes, failed and lost to-follow-up, constituted only 1% combined. Less than 
1% of TB cases recurred during the study period. Among the recurrent cases, more 
than 80% were due to relapses. Male gender was a risk factor for both death as 
outcome and for TB recurrence. Older age increased the risk for death, whereas 
younger age increased the risk for TB recurrence. Comorbidities were associated 
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with the risk of death in all age groups. Drug resistance predicted non-successful 
treatment outcomes other than death. Pulmonary site of disease strongly correlated 
with the risk for TB recurrence in the long run. Furthermore, substantial deviations 
from guidelines in notified treatment outcomes and prescribed treatments in the 
episodes preceding recurrence among recurrent TB cases were observed.  
In conclusion, the rate of successful treatment outcomes is clearly below the 
target of 85% set by World Health Organization. This is mainly due to the high 
proportion of death as outcome. TB recurrence is rare. The high mean age among 
Finnish-born cases and the presence of comorbidities at least partially explain the 
high proportion of death as the outcome. However, because most fatal cases die 
early, better awareness of TB among the population and health-care professionals is 
needed to reach early suspicion, timely diagnosis and treatment of TB. Furthermore, 
special attention should be paid to choosing correct treatment regimens and to 
promoting treatment adherence using directly observed treatment for younger male 
patients and patients with drug-resistant strains, because they show high relative risks 
for non-successful treatment. Finally, shortcomings observed in allocation of 
treatment outcomes in the cohort and in prescribed treatment regimens in episodes 
preceding recurrence show that a need exists to review national guidelines and to 
further train the physicians treating TB cases. 
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TIIVISTELMÄ 
Tuberkuloosin tehokas hoito on tärkeää sekä potilaan parantamiseksi että uusien 
tartuntojen estämiseksi, koska tuberkuloosi tarttuu ilman välityksellä ihmisestä 
toiseen. Tuberkuloosin hoidon laatua arvioidaan yleisimmin määrittämällä hoidon 
lopputulos. Tämä kuvastaa hoidon tehoa lyhyellä aikavälillä. Pysyvämpää 
paranemista voidaan tarkastella tutkimalla tuberkuloosin uusiutumista. 
Uusiutuminen voi johtua joko aiemmin hoidetun taudin uudelleen aktivoitumisesta 
tai uudesta tartunnasta. Tutkittaessa tuberkuloosin hoidon laatua on tärkeää erottaa 
nämä syntymekanismit, koska vain taudin uudelleen aktivoituminen kuvastaa 
aiemman tuberkuloosiepisodin hoidon riittämättömyyttä. 
Tämän väitöstutkimuksen tarkoituksena oli tarkastella tuberkuloosin hoidon 
laatua Suomessa arvioimalla hoidon lopputuloksia vuoden kohdalla hoidon alusta 
laskien, tuberkuloosin uusiutumista pidemmällä aikavälillä sekä hoidon 
epäonnistumisen riskitekijöitä. Uusiutuneiden tapausten kohdalla oli tarkoituksena 
erotella taudin uudelleen aktivoitumisesta ja uudesta tartunnasta johtuvat tapaukset. 
Lisäksi arvioimme ilmoitettujen hoidon lopputulosten sekä uusiutuneille tapauksille 
edeltävässä tuberkuloosiepisodissa annetun hoidon asianmukaisuutta. 
Kyseessä oli taannehtiva kohorttitutkimus, joka pohjautui valtakunnalliseen 
tartuntatautirekisteriin ilmoitettuihin tuberkuloositapauksiin. Tutkimuksessa 
arvioitiin kahdeksan vuoden tutkimusjakson aikana rekisteriin ilmoitettujen 
mikrobiologisesti varmennettujen keuhkotuberkuloositapausten hoidon 
lopputuloksia. Tapauksia oli 1416, kun monilääkeresistentit tuberkuloosikannat oli 
suljettu pois tutkimuksesta. Tuberkuloosin uusiutumista tutkittiin 19 vuoden 
tutkimusjakson aikana, ja tässä kohortissa oli mukana 8084 tuberkuloositapausta. 
Tuberkuloosin uusiutumisen syntymekanismi pystyttiin tutkimaan niiltä tapauksilta, 
joilla oli tuberkuloosia aiheuttavan bakteerin, Mycobacterium tuberculosis’n, kannat 
tallessa molemmista tautiepisodeista. Erottelu tehtiin käyttämällä 
kokogenomisekvensointia, joka on uusi genotyypitys-menetelmä. 
75 %:lle tapauksista oli ilmoitettu hyvä hoidon lopputulos. Kuolema ennen hoitoa 
tai hoidon aikana oli toiseksi yleisin hoidon lopputulosryhmä 16 %:n osuudella. Muut 
erityisen huonot hoidon lopputulokset, epäonnistunut hoito ja hoito jäänyt kesken, 
olivat harvinaisia yhteensä vain yhden prosentin osuudella. Alle prosentilla 
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tapauksista tuberkuloosi uusiutui tutkimusjakson aikana. Yli 80 % uusiutumisista 
johtui taudin uudelleen aktivoitumisesta. Miessukupuoli oli sekä kuoleman että 
tuberkuloosin uusiutumisen riskitekijä. Vanhemmilla ikäryhmillä oli suurempi 
kuolemanriski, kun taas nuoremmilla tapauksilla oli suurempi tuberkuloosin 
uusiutumisen riski, vaikka eroavuudet seuranta-ajoissa ikäryhmien välillä otettiin 
huomioon. Liitännäissairaudet lisäsivät kaikkien ikäryhmien riskiä hoidon 
lopputulokselle kuollut. Lääkeresistentti tuberkuloosikanta ennusti muita huonoja 
hoidon lopputuloksia paitsi kuolemaa. Tuberkuloosin uusiutumisen riski pidemmällä 
aikavälillä oli voimakkaasti suurempi keuhkotuberkuloosia sairastavilla kuin 
keuhkojen ulkopuolista tuberkuloosia sairastavilla. Lisäksi havaitsimme, että 
ilmoitetut hoidon lopputulokset sekä uusiutuneiden tapausten edeltävässä 
tuberkuloosiepisodissa saama hoito poikkesivat merkittävissä määrin kansallisista ja 
kansainvälisistä ohjeista.  
Yhteenvetona voidaan todeta, että hyvän hoidon lopputuloksen osuus on selvästi 
pienempi kuin Maailman terveysjärjestön WHO:n tavoitteeksi asettama 85 %. Tämä 
johtuu pääasiassa kuolleiden suuresta osuudesta. Tuberkuloosin uusiutuminen on 
harvinaista. Kuolleiden suurta osuutta selittävät ainakin osittain suomalaissyntyisten 
tuberkuloosipotilaiden korkea keski-ikä sekä liitännäissairauksien yleisyys 
tuberkuloosia sairastavilla. Koska suurin osa kuolemantapauksista ilmenee joko 
ennen tuberkuloosin hoidon aloitusta tai kahden ensimmäisen hoitokuukauden 
aikana, tuberkuloosin tunnettavuuden parantaminen sekä väestön että 
terveydenhuoltohenkilöstön keskuudessa on tarpeen, jotta tätä harvinaista tautia 
osataan epäillä ja diagnosoida sekä aloittaa hoito ajoissa. Lisäksi on tärkeää huolehtia 
oikean lääkeyhdistelmän valinnasta sekä hoidon tukemisesta käyttäen valvottua 
lääkehoitoa erityisesti nuoremmilla miehillä ja henkilöillä, joilla on lääkeresistentti 
kanta, koska näillä potilasryhmillä on selvästi lisääntynyt hoidon epäonnistumisen 
riski. Havaitsemamme poikkeamat ilmoitetuissa hoidon lopputuloksissa sekä 
uusiutuneiden tapausten edeltävän tuberkuloosiepisodin hoidoissa viittaavat siihen, 
että tuberkuloosia hoitavat lääkärit tarvitsevat lisäkoulutusta ja kansallisia ohjeita on 
syytä tarkentaa. 
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1 INTRODUCTION 
Tuberculosis (TB) is currently a poorly known disease among inhabitants of the 
Western world. However, TB still ranks as one of the top ten causes of death globally 
according to the World Health Organization (WHO) (WHO, 2019a). TB afflicts 
especially populous and poorer areas in the world (Reid et al., 2019). In high-income 
settings, most TB cases are among certain more vulnerable risk groups, such as 
immigrants from countries with a high TB-incidence, persons with social risk factors 
or with an impaired immune system due to a disease, e.g. HIV-infection and diabetes, 
or receiving immune suppressive medication (Lönnroth et al., 2015). A major 
concern in Europe is the emergence of multi-drug resistant (MDR) strains, especially 
in countries of the former Soviet Union (WHO, 2019a). 
The rate of annually diagnosed TB cases in Finland has declined from 
approximately 7000 to the current 250 during the last 60 years (Jaakola et al., 2018; 
Tala-Heikkilä, 2003). The major risk group for TB is elderly Finnish-born persons 
who become sick due to reactivation of an infection transmitted decades ago. 
However, the epidemiologic situation is changing with increasing immigration and a 
decreasing TB incidence among the native population (Räisänen et al., 2015). 
Immigrants constitute more than a third of annual TB cases currently (Jaakola et al., 
2018). 
TB is caused by a slow-growing bacterium, called Mycobacterium tuberculosis (M. 
tuberculosis), and its transmission is airborne from human to human. A long treatment 
period of at least 6 months with multiple drugs is needed to ensure permanent 
eradication of the bacteria (Migliori et al., 2018). Adequate TB treatment is a key 
element both to heal the patient and to decrease transmission together with early 
diagnoses and appropriate contact investigations. WHO recommends evaluating 
treatment outcomes for all TB cases (WHO, 2014).  
Evaluation of treatment outcomes reflects the efficacy of treatment in a shorter 
period. More permanent cures can be assessed by evaluating TB recurrence (Rosser, 
Marx, & Pareek, 2018). A recurrent TB case can occur in two ways; as re-infection 
or as relapse. Re-infection means that a person gets a new infection with a new strain 
of M. tuberculosis after being treated for tuberculosis. Relapse occurs due to 
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endogenous reactivation with the same strain of M. tuberculosis as in the former TB 
episode, which reflects an insufficient treatment of the former TB episode. 
Distinguishing relapses from re-infections can be established by genotyping 
methods when isolates of M. tuberculosis are available from both TB episodes. Whole 
genome sequencing (WGS) is a new method for genotyping with more 
discriminatory power compared to traditional genotyping methods ( Nikolayevskyy 
et al., 2019). WGS is expected to replace the currently used heterogeneous methods 
for species detection, rapid drug resistance prediction and genotyping (Amlerova et 
al., 2018; Quan et al., 2018). 
Evaluating the quality of TB treatments is important to identify high-risk groups 
and to improve national TB control programs. This dissertation was carried out to 
evaluate the quality of tuberculosis treatment in Finland by assessing treatment 
outcomes at one year and recurrence of tuberculosis in a longer period and to 
determine risk factors for non-successful treatment. Relapses were distinguished 
from re-infections using WGS.  
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2 REVIEW OF THE LITERATURE 
2.1 Tuberculosis  
2.1.1 History 
Tuberculosis is an ancient disease among humankind. It has been stated that early 
hominids in East Africa were infected by an early progenitor of M. tuberculosis three 
million years ago (Gutierrez et al., 2005). Typical skeletal deformities for tuberculosis 
have been found in Egyptian mummies dating back to 2400 BC, and existence of M. 
tuberculosis complex in mummies has been shown using modern molecular 
technology methods, nucleic acid amplification and genotyping (Morse et al., 1964; 
Zink et al., 2003). Additionally, 2300-3300 years old written documents describing 
tuberculosis have been found in China and India (Barberis et al., 2017). 
The incidence of tuberculosis in Europe was proportionately low in the Middle 
Ages (Amlerova et al., 2018). The incidence subsequently started to rise and was 
augmented by poor social conditions during the industrial revolution (Barberis et al., 
2017). Tuberculosis especially afflicted lower social groups: up to one third of 
employees and tradesmen compared to one sixth of the upper class died of TB at 
the beginning of the 19th century (Barberis et al., 2017). The etiology of TB was 
especially debated during the 19th century. Finally, the infectious etiology was 
confirmed when the causative bacteria, now called Mycobacterium tuberculosis, was 
isolated by Robert Koch in 1882 (Koch, 1882). This discovery was a milestone for 
the study of TB and was followed by several inventions, such as the theory of 
transmission via droplet infection in 1897, the development of vaccine Bacillus 
Calmette-Guérin (BCG) in 1921 and, finally, the invention of the first anti-
tuberculosis drugs, streptomycin in 1944 and isoniazid in 1952 (Daniel, 2006; Netea 
et al., 2014). 
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2.1.2 Epidemiology 
Approximately 10 million people are estimated to fall ill and almost 1.5 million 
people to die with TB annually, which ranks TB as the number one cause of death 
among infectious diseases globally (WHO, 2019a). TB especially afflicts populous 
and poorer areas in the world: two thirds of new cases occur in eight countries of 
South Asia and Africa, such as India, China, Indonesia and Nigeria (Reid et al., 2019). 
TB seems to be more common among males: more than 60% of notified cases are 
males (WHO, 2019a). 
Tuberculosis was declared a public health emergency by WHO in 1993 
(Nakajima, 1993). WHO additionally launched the Stop TB Strategy for global 
tuberculosis control in 2006 and the newest END TB Strategy in 2015 with the target 
of reducing TB incidence by 90% and TB deaths by 95% by year 2035 (WHO, 2006, 
2015). TB incidence has decreased by approximately 1.4%/year and mortality by 
3%/year since year 2000, yet the decline is far from reaching the targets (WHO, 
2019a). Two particular reasons for this are the emergence of human 
immunodeficiency virus (HIV) and TB co-infection, especially in sub-Saharan 
Africa, and the MDR-TB strains, i.e., strains resistant to two of the most effective 
TB drugs, rifampicin and isoniazid, in India, China and countries of the former 
Soviet Union (Furin et al., 2019). 
The incidence of TB in Finland was about 170/100 000 in 1960, the same 
magnitude as in many developing countries nowadays (Tala-Heikkilä, 2003). The 
decline of TB incidence in Finland has been one of the greatest declines in Europe. 
Finland reached the target of becoming a low-incidence country in 2001 with less 
than 10/100 000 new cases diagnosed annually (Hulkko et al., 2010). Since then, the 
incidence has still decreased to current 4-5/100 000 (Jaakola et al., 2018). In contrast 
to many European countries, such as Sweden, Denmark and the Netherlands, where 
TB mainly occurs among immigrants, tuberculosis in Finland is still a disease of 
elderly natives due to the reactivation of an infection transmitted decades ago 
(ECDC/WHO regional office for Europe, 2019). However, the proportion of 
immigrants among TB cases has increased from 4% in 1995-1996 to 40% in 2017 
(Jaakola et al., 2018; Vasankari et al., 2007). Despite the alarming MDR situation in 
the Russian Federation, only 5-8 MDR-cases are diagnosed annually in Finland. 
Cases with extremely drug resistant isolates (XDR), i.e., MDR isolates with additional 
resistance to at least one fluoroquinolone and one injectable drug, have been 
sporadic (Jaakola et al., 2018; Vasankari et al., 2012).  
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2.1.3 Mycobacteria 
Mycobacteria are aerobic gram-positive bacteria with about 200 different species 
recognised so far (Forbes et al., 2018; Tortoli, 2014). Tuberculosis is caused by 
closely related mycobacteria species belonging to the M. tuberculosis complex, which 
includes, in addition to the most prevalent species, M. tuberculosis, also M. bovis, M. 
bovis BCG, M. africanum, M. microtii and M. canettii (Forbes et al., 2018). Leprosy, a still 
existing disease especially in India, Brazil and Indonesia, is caused by M. leprae (Naaz 
et al., 2017). Most of the known mycobacteria species are not transmitted between 
humans and are called non-tuberculous or environmental mycobacteria. 
2.1.4 From transmission to infection and disease 
Transmission of tuberculosis can be described as a simplified process: a person with 
TB in the respiratory tract generates infectious particles that are aerosolised through 
forceful exhaling, such as coughing or sneezing; another person who inhales these 
aerosolised particles containing M. tuberculosis bacteria may become infected and 
develop the active disease (Churchyard et al., 2017; Turner et al., 2017). Many factors 
can affect this process. 
Only persons with active pulmonary or laryngeal TB can transmit the disease with 
the exception that TB outside the respiratory tract may be transmitted in operations 
or other procedures when aerosolised particles are formed. Infectiousness depends 
on the state of the disease, and persons with sputum smear positivity and cavitary 
lung lesions in chest radiography are considered particularly contagious (Churchyard 
et al., 2017; Zelner et al., 2014). The events in humans after exposure to M. tuberculosis 
are not well understood (Cadena et al., 2016). The alveolar macrophages of an 
exposed person play a major role in trying to destroy inhaled particles containing M. 
tuberculosis bacteria at first, and T-cell-mediated immune response is developed in 
about six weeks (Cadena et al., 2016). The bacteria may be destroyed by granuloma 
formation. If not destroyed, the bacteria may spread to distant parts of the body. 
Latent tuberculosis infection (LTBI) is a state of persistent bacterial viability, 
immune control and no evidence of active tuberculosis, and it can last for decades, 
even throughout the lifetime (Getahun et al., 2015). Interferon gamma release assay 
(IGRA) and tuberculin skin test (Mantoux) reflect the T-cell response to M. 
tuberculosis antigens and become positive when a measurable T-cell response has been 
induced (Cadena et al., 2016). LTBI can be detected using the IGRA or tuberculin 
skin test. 
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A systematic review including 95 studies from countries with a low or moderate 
incidence of TB described that the prevalence of LTBI was 28% among contacts of 
patients with TB (Fox et al., 2013). Active TB disease was diagnosed for 1.4% of 
contacts during the study period. The period with the highest risk to develop active 
TB is the first year after exposure, but the risk lasts throughout the lifetime and the 
overall risk for active TB is about 3% (Fox et al., 2013). Factors increasing the risk 
of LTBI proceeding into active disease are, e.g., impaired immune system because 
of a disease, such as HIV-infection and diabetes, undernutrition or immune 
suppressive medication, smoking and belonging to the under 5 years age group (Al-
Rifai et al., 2017; Dowdy et al., 2014; Zhang et al., 2017).  
2.1.5 Clinical picture  
Tuberculosis infection can affect almost any organ or tissue of the human body. The 
most prevalent site of the disease is in the lungs. TB is diagnosed only outside the 
lung parenchyma, called extrapulmonary TB, in approximately 15-20% of cases, with 
the most common sites of disease recognised as lymph nodes, pleura, bones and 
joints, genitourinary tract and meninges (Peto et al, 2009; WHO, 2019a). Factors 
favoring the development of extrapulmonary disease, instead of pulmonary disease, 
are female gender and origin from high-incidence country, which may reflect a 
shorter time since infection and the existence of certain lineages of M. tuberculosis (Al-
Ghafli et al., 2019; Click et al., 2012; Peto et al., 2009).  
The TB symptoms are the same as in many other chronic infections and some 
other diseases, such as fever, night sweats, loss of weight and fatigue. Patients with 
pulmonary TB often have a cough, which is productive or dry and has lasted for 
more than 2-3 weeks, dyspnea and chest pain as well as occasional haemoptysis. 
Extrapulmonary TB manifestations may represent with, e.g., pain and edema in the 
affected organ. Sometimes patients with active TB do not recognise any symptoms, 
especially those who are immunocompromised (Storla et al., 2008). 
2.1.6 Diagnostic procedure 
A chest radiography should always be taken when a suspicion for TB has been 
awaken due to, e.g., typical symptoms and/or risk factors. Typical findings include 
pneumonia-like infiltrates, nodules and cavitary lesions, especially in the upper lobes 
or superior segments of lower lobes. Adenopathy, pleural effusion and widely 
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distributed small nodules (miliary TB) may also be detected (Rozenshtein et al., 
2015). High-resolution computed tomography of the chest is more sensitive and 
specific than conventional chest radiography for diagnosing pulmonary TB 
(Raghuvanshi et al., 2016). 
An intention to acquire at least three sputum samples is crucial, especially when 
pulmonary TB is suspected (Migliori et al., 2018). Expectorating sputum samples can 
be induced by inhaling hypertonic saline. Bronchoscopy is established to obtain 
samples by aspirating bronchial washings, as well as bronchoalveolar lavage and by 
needle aspiration when needed, if satisfactory sputum samples cannot be produced  
(Mondoni et al., 2017). Obtaining samples from affected organs is crucial when 
diagnosing extrapulmonary TB. Furthermore, HIV should be tested for all persons 
suspected of having TB (Migliori et al., 2018).  
The diagnosis can be based on clinical and radiological features when TB cannot 
be microbiologically confirmed (Migliori et al., 2018). Tissue samples obtained by 
biopsy, surgery or at autopsy that show a typical histological picture, granulomas 
with caseating necrosis, can endorse the diagnosis of TB, even though not specific 
for TB. Indefinite cases may be confirmed by a positive response to TB treatment. 
2.1.7 Laboratory methods for diagnosis and drug susceptible testing  
Smear microscopy for acid fast bacilli is the most common way to detect 
mycobacteria directly from clinical specimens. Smear microscopy is non-sensitive 
and non-specific even though fast and inexpensive. (Eskola et al., 2004). 
M. tuberculosis complex can be directly detected and distinguished with high 
sensitivity and specificity from other mycobacteria in smear positive samples using 
nucleic acid amplification tests (NAAT), such as the widely used commercial test, 
GeneXpert® (Yan et al., 2016). NAA tests are rapid, which is particularly important 
for both severely ill patients and for pulmonary TB cases with a positive sputum 
smear, because the patient is considered highly contagious if mycobacteria belong to 
M. tuberculosis complex. NAA tests are also used for rapid diagnostics of smear 
negative samples, but the sensitivity of NAA tests is lower and depends on the type 
of sample (Altez-Fernandez et al., 2017; Pormohammad et al., 2019; Shaw et al., 
2019; Tian et al., 2015). Commercial NAA tests, such as Xpert MTB/RIF®, can also 
detect mutations in the most common rifampicin resistance conferring gene, rpoB, 
which can be used as a proxy for MDR-TB. 
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Culture is still the gold standard for laboratory diagnostics of tuberculosis despite 
the advances in laboratory methods. It is rather sensitive and enables identification 
of species, drug susceptibility testing and the use of genotyping methods for, e.g., 
the evaluation of transmission chains (Forbes et al., 2018). However, culture is a slow 
method, because it takes usually 2-6 weeks for M. tuberculosis to grow sufficiently.  
The species of mycobacteria, when cultured, can be identified rapidly using 
commercial tests such as Line-probe assays, based on direct probe hybridisation and 
sequence-based techniques (Forbes et al., 2018). When MDR is suspected on a 
clinical basis, e.g., immigrants from countries with a high proportion of MDR strains, 
or the result of Xpert MTB/RIF® shows resistance to rifampicin, an additional 
commercial rapid test, such as Hain genotype MTBDR plus®, can be performed 
(Dominguez et al., 2016). It detects mutations in the most common rifampicin and 
isoniazid resistance conferring genes, rpoB, katG and inhA. An additional test can be 
performed when MDR is strongly suspected for rapid detection of resistance to 
fluoroquinolones and injectable drugs (Dominguez et al., 2016). A consensus 
statement given by the Tuberculosis Network European Trials Group and Research 
Excellence to Stop TB Resistance announces that the final interpretation of drug 
resistance should currently be made by phenotypic drug susceptibility testing (DST) 
based on minimal inhibitory concentration analysis of cultured specimens 
(Dominguez et al., 2016). 
2.2 Genotyping for TB isolates 
The DNA sequence of an isolate is analysed by molecular methods and compared 
to the sequence of another isolate or a reference sequence in bacteria genotyping. 
Genotyping methods have been used since the early 1990s to distinguish strains of 
M. tuberculosis for epidemiologic research (Das et al., 1993; Hawken et al., 1993; Kato-
Maeda et al., 2011). Genotyping methods have been applied for several purposes, 
such as investigation of TB outbreaks, assistance in contact tracing, detection of 
laboratory cross-contamination, characterisation of molecular epidemiology in 
certain populations and distinguishing relapses from re-infections among recurrent 
TB cases (Jagielski et al., 2014; Puustinen et al., 2003; Smit et al., 2014; van Soolingen 
et al., 1999). 
 
23 
2.2.1 Traditional genotyping methods 
Several genotyping methods have been developed during the last decades. The most 
common methods used for M. tuberculosis are IS6110-restriction fragment length 
polymorphism (IS6110-RFLP), multilocus variable number tandem repeat 
genotyping (MIRU-VNTR) and spoligotyping (Amlerova et al., 2018). These 
methods are based on the analysis of differing numbers or locations of specific 
markers in the genome of M. tuberculosis (Bryant et al., 2013). 
The first genotyping method, called fingerprinting, was based on polymerase 
chain reaction (PCR) amplification and restriction of certain sequences of M. 
tuberculosis followed by analysis by electrophoresis. IS6110-RFLP detects the 
distribution of markers that are insertion elements, i.e. fragments of genome capable 
of multiplying and inserting themselves anywhere in the genome. In MIRU-VNTR, 
the number of copies of tandem repeated sequences, which vary among strains, is 
detected by PCR. Polymorphism of a genomic region called direct repeat region, is 
analysed by spoligotyping (Amlerova et al., 2018; Ei et al., 2016; Jagielski et al., 2014). 
The traditional genotyping methods have been internationally harmonised 
allowing for comparison of results obtained in different laboratories. However, 
traditional genotyping methods have major disadvantages. They detect only short 
parts of genomic DNA resulting in restricted data. Their ability to discriminate 
strains varies depending on the method and they have insufficient capability to 
distinguish strains that are genetically highly related. Furthermore, some methods are 
laborious, time consuming and require advanced technical equipment and software 
(Cabibbe et al., 2018; Quainoo et al., 2017). The cost-effectiveness of their use has 
also been questioned (Mears et al., 2014). Thus, better tools for genotyping are 
needed.  
2.2.2 Whole genome sequencing 
The DNA sequence of the whole genome of M. tuberculosis can be analysed using 
whole genome sequencing, except for the so-called repetitive sequences, which are 
hard to read. The sequence is compared to reference genome of M. tuberculosis and 
mutations in base pairs, i.e., single nucleotide polymorphism (SNPs), insertions and 
deletions can be detected (Cabibbe et al., 2018). WGS can be used to identify species 
of mycobacteria, to detect mixed infections and to detect mutations conferring drug 
resistance in addition to using WGS as a genotyping method (Cabibbe et al., 2018; 
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Pankhurst et al., 2016; van Soolingen et al., 2016; Zhang et al., 2013). WGS may also 
detect novel drug resistance mutations (Witney et al., 2017) . 
Compared to traditional genotyping methods, WGS is more powerful for strain 
differentiation and gives more accurate information about transmission chains and 
clusters, thus avoiding erroneous assessment of clusters (Nikolayevskyy et al., 2019). 
The average mutation rate of M. tuberculosis genome varies between 0.3-1.1 
SNPs/year (Bryant et al., 2013; Norheim et al., 2017; Walker et al., 2013). Among 
isolates from patients with confirmed epidemiologic links, the number of SNPs 
between isolates has varied from 0-5 (Bryant et al., 2013; Casali et al., 2016; Walker 
et al., 2013). Recent studies have proposed <6 SNPs and >12 SNPs as cut offs to 
indicate and exclude recent (in 3 years) transmission, respectively (Nikolayevskyy et 
al., 2019; Nikolayevskyy et al., 2016). 
2.3  Treatment of tuberculosis 
The standard treatment regimen for cases with drug-susceptible TB includes an 
intensive phase for 2 months with 4 anti-TB drugs, isoniazid, rifampicin, 
pyrazinamide and ethambutol. Pyrazinamide and ethambutol can be discontinued 
for consolidation phase lasting for four months once resistance to rifampicin and 
isoniazid is excluded (Migliori et al., 2018). In Finland, the use of a fourth drug, 
ethambutol, during the intensive phase was included in recommendations in 2013 
(Sosiaali- ja terveysministeriö, 2013).  
Recommendations for treatment prolongation vary, including cases with, e.g., 
cavitary or extensive pulmonary TB with persistently positive sputum culture at two 
months after treatment initiation, TB affecting the central nervous system, bone and 
joint TB and impaired immune system (American Thoracic Society, CDC, & 
Infectious Diseases Society of America, 2003; Horsburgh et al., 2015; Rajasekaran et 
al., 2018; Sosiaali- ja terveysministeriö, 2013; WHO, 2017b). 
Adverse effects, such as nausea and vomiting, rash and hepatotoxic effects, are 
very common during TB treatment. A prospective cohort study, including cases with 
drug susceptible isolates with standard treatment, reported that at least one anti-TB 
drug had to be interrupted or discontinued due to adverse reaction for 15% of the 
cases (Lv et al., 2013). 
WHO and European Center for Disease Prevention and Control (ECDC) 
currently recommend a patient-centered approach to treatment including the use of 
directly observed treatment (DOT), when appropriate (Migliori et al., 2018; WHO, 
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2017b). In Finland, the use of DOT has been recommended for certain risk groups 
since 2006 and for all patients since 2013 (Sosiaali- ja terveysministeriö, 2013). 
2.3.1 Treatment for cases with drug resistant isolates 
Treatment regimen and duration should be individualised on the basis of known or 
assumed drug susceptibility for cases with confirmed drug resistance or with a strong 
suspicion for drug resistance and necessitated treatment initiation without drug 
susceptibility results. Current guidelines by WHO for high-resource countries advise 
that cases with MDR-TB should be started with MDR regimens, which are based on 
a combination of at least 4-5 likely susceptible second-line drugs, including a newer 
drug, bedaquiline, and the treatment period should last for at least 18-20 months 
(WHO, 2019b). 
2.3.2 Surgical interventions for treatment of TB 
Anti-TB medication solely is not enough for permanent cure for some cases with 
extrapulmonary TB manifestations. Patients may benefit from drainage of pleural 
and pericardial effusions (Imazio et al., 2013; Shaw et al., 2019; Wiysonge et al., 
2017). Surgery may be needed for some extrapulmonary TB manifestations, such as 
pleural empyema and spinal tuberculosis with neurological deficits, large abscesses 
or deformity (Dunn et al., 2018; Shaw et al., 2019). The introduction of anti-TB 
medications in the 1950s and 1960s almost replaced surgery in the treatment for 
pulmonary TB, but the emergence of MDR- and XDR-TB has brought surgery as 
an option. Surgery should be considered for pulmonary MDR-patients with 
unilateral disease and sufficient lung function, if medical treatment has failed or the 
risk of failure or TB relapse is high, e.g., XDR-cases (Dheda et al., 2017; Lange et al., 
2019; Sharma et al., 2019). 
2.3.3 Contact investigations and follow-up  
The need for contact investigations should be assessed for each case to stop ongoing 
transmission (Migliori et al., 2018). An attempt to obtain sputum samples for smear 
microscopy and culture should be made for pulmonary TB cases to follow up 
response to treatment, at least at the end of the intensive phase. Obtaining sputum 
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samples monthly is recommended for all and especially for MDR-cases. 
Furthermore, clinical response to treatment should be assessed monthly for all TB 
cases. (Migliori et al., 2018; WHO, 2019b).  
2.4 TB treatment outcomes 
Adequate TB treatment, in addition to healing the patient, is a key element to 
decrease transmission together with early diagnoses and appropriate contact 
investigations. WHO set a global target in 1991 to cure 85% of pulmonary TB 
patients under treatment (WHO, 1991). A constitutive way to evaluate the 
functionality of a national TB control program is TB treatment outcome monitoring. 
Recommendations for treatment outcome monitoring in Europe were published by 
a Working Group of WHO and the International Union against Tuberculosis and 
Lung Disease (IUATLD) in 1998 (Veen et al., 1998). Notifying treatment outcomes 
to National Infectious Disease Register (TTR) for microbiologically confirmed 
pulmonary TB cases has been compulsory in Finland since 2007 (Sosiaali ja 
terveysministeriö, 2006). 
2.4.1 Current guidelines for outcome evaluation 
WHO recommends assigning treatment outcomes with six categories for all TB 
cases at the time of treatment cessation. Treatment outcomes should be assigned 
separately for cases with rifampicin resistant and MDR isolates. (WHO, 2014). 
Recommendations for European countries made by the ECDC together with the 
WHO office for the European Region are consistent with global recommendations, 
except that outcomes should be notified at the latest at 12 months after treatment 
initiation (ECDC/WHO regional office for Europe, 2013). Hence, an additional 
outcome group ‘still on treatment’ is subsumed. Table 1 presents the definitions for 
outcome groups by the WHO and ECDC/WHO regional office for Europe. Finnish 
guidelines for outcome reporting and grouping are consistent with European 
guidelines with the exception that treatment outcomes are not notified for 
extrapulmonary TB cases, and for pulmonary TB cases without microbiological 
confirmation outcomes have been notified only since 2017 (Jaakola et al., 2018). 
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Table 1. Definitions for treatment outcome grouping by WHO and ECDC/WHO regional office 
for Europe  
Treatment 
outcome WHO 
2013 
Treatment outcome 
for Europe 
ECDC/WHO 2013 
Definition for outcome 
Cured¹ Cured¹ A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear- or culture-negative in the last 
month of treatment and on at least one previous occasion 
Treatment 
completed¹ 
Treatment completed¹ Treatment completed, but does not meet the criteria to be classified as 
cure or treatment failure 
Failed Failed A TB patient whose sputum smear or culture is positive at month 5 or 
later during treatment 
Lost to follow-up² Lost to follow-up³ A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more 
Died  Died  A TB patient who dies for any reason before starting or during the 
course of treatment 
Not evaluated⁴ Not evaluated⁴ A TB patient for whom no treatment outcome is assigned. This 
includes cases “transferred out” to another treatment unit as well as 
cases for whom the treatment outcome is unknown to the reporting 
unit 
- Still on treatment Patient still on treatment at 12 months without any other outcome 
during treatment 
¹Cured+treatment completed=successful treatment outcomes  
²Nominated as default in earlier versions of guidelines by WHO 
³Nominated as treatment interrupted in earlier versions of guidelines by ECDC/WHO regional office for Europe 
⁴Transferred out cases were notified separately in earlier versions of guidelines by WHO/ECDC 
Modified from references (ECDC/WHO regional office for Europe, 2013; WHO, 2014) 
2.4.2 Rates for successful treatment outcomes 
Among the 6.4 million reported new and relapse TB cases globally in 2017, the 
average treatment success rate, i.e. proportions of cases with outcomes cured and 
treatment completed combined, was 85%. The treatment success rate reported by 
the WHO for the European region, 78%, is the second lowest among the six WHO 
regions. (WHO, 2019a). Many explanations may be presented for the widely differing 
success rates between regions, such as differences in demographics among TB 
patients, including the proportions of elderly patients, cases with risk factors (e.g., 
substance abuse and comorbidities) and cases with MDR isolates, as well as 
differences in coverage of outcome reporting (Guthmann et al., 2020; Karo et al., 
2015). There may also be crucial differences in outcome evaluation procedures, e.g., 
who performs outcome evaluation, reflected by some countries with high TB 
incidences reporting astonishingly high treatment success rates, such as 96% in 
Ethiopia and 94% in Cambodia (WHO, 2019a). 
Among European countries, recommendations for reporting and the coverage of 
routine outcome reporting vary widely (ECDC/WHO regional office for Europe, 
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2019). A study that included surveillance data from 18 European countries in 2002-
2011 showed a distribution of treatment success rate from 56% in Hungary to 89% 
in Norway (Karo et al., 2015).  
2.4.3 Rates for non-successful treatment outcomes 
Among the 15% of cases in 2017 with other than successful treatment outcome 
notified globally, not evaluated was the most common outcome, followed by 
outcomes died, lost to follow-up and failed, respectively (WHO, 2019a). The most 
common non-successful outcome for cases notified in the WHO European region 
in 2016 was died with an 8% proportion, followed by outcomes not evaluated (7%), 
lost to follow-up (5%), failed (4%) and still on treatment (1%). The notified 
proportion of cases with outcome died varies widely from 0% in small countries with 
very few TB cases, Iceland and Lichtenstein, up to 16-20% in countries with a high 
proportion of elderly cases, Croatia, Czech Republic and Slovenia. (ECDC/WHO 
regional office for Europe, 2019). 
2.4.4 Definitions for treatment outcome categories and exclusion criteria 
used in studies  
A systematic review for treatment outcome studies from 10 European countries 
found that differing methods for treatment outcome evaluation limit international 
comparisons (van Hest et al., 2013). For example, 12 different outcome categories 
were used instead of the 7 suggested for European countries (ECDC/WHO regional 
office for Europe, 2013). Heterogeneity in terminology for outcomes is also 
confusing, e.g., outcome lost to follow-up currently used to describe premature 
interruption of treatment was used in some older studies to describe cases who 
disappeared before the end of treatment (Antoine et al., 2007; Ditah et al., 2008).  
Most older and some newer studies report outcomes for culture-positive 
pulmonary TB cases solely, whereas a few newer studies report outcomes for all 
notified TB cases (Karo et al., 2015; Stosic et al., 2020). Furthermore, exclusion 
criteria among studies vary widely. Some studies excluded patients who did not 
receive treatment due to TB diagnosis established after death or due to 
disappearance, patients with unreported outcome and patients under 18 years of age 
(Guthmann et al., 2020; Pradipta et al., 2018).  
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Outcomes are usually combined into groups with varying combinations to 
evaluate risk factors for other than successful outcomes. Many studies compare cases 
with successful treatment outcomes to cases with all other treatment outcomes 
combined, called non-successful or unsuccessful outcomes (Antoine et al., 2007; 
Karo et al., 2015; Kherad et al., 2009). A common way is also to make three outcome 
groups by distinguishing cases with successful outcomes, cases with outcome died 
and cases with other unsatisfactory outcomes, including either all other outcomes or, 
e.g., outcomes lost to follow-up, failed and proportionately also a former outcome 
category transferred out before or during TB treatment, which is included in the 
outcome category not evaluated in current guidelines (Farah et al., 2005; Pradipta et 
al., 2018; Stosic et al., 2020; Vasankari et al., 2007). The rationale for this grouping is 
that cases with outcomes lost to follow-up, failed and transferred out may transmit 
the disease further when the site of disease is pulmonary. 
Finally, cases with death as outcome have been  discriminated into successful and 
non-successful outcome categories based on the assessment of whether TB was 
reported as a cause of death or not (Ditah et al., 2008; Guthmann et al., 2020). 
Furthermore, some studies have distributed cases with outcome still on treatment to 
successful and non-successful treatment groups based on the reason for treatment 
elongation (Cegolon et al., 2010; Ditah et al., 2008). 
2.4.5 Death as outcome 
WHO and ECDC recommend to report death as outcome for all TB cases who die 
before or during TB treatment irrespective of the cause of death. Two studies from 
the U.S. showed that among fatal cases early deaths are common, as a quarter died 
before and more than 40% died in two months after initiation of treatment (Nguyen 
et al., 2011; Pascopella et al., 2014). 
Several studies using multivariable models have shown that increasing age is the 
strongest predictor for death as outcome (Stosic et al., 2020; Vasankari et al., 2007). 
Male gender has also been associated with a fatal outcome in a few studies (Horne 
et al., 2010; Vasankari et al., 2007). Immigrants and asylum seekers have been related 
to a lower risk for death as outcome, which may reflect differences in other risk 
factors, such as comorbidities and substance abuse as well as earlier suspicion for 
TB (Horne et al., 2010; Pradipta et al., 2018). Cases infected with HIV and cases 
receiving immunosuppressive medication have been associated with a higher risk for 
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death in some studies from low-incidence countries (Beavers et al., 2018; Nguyen et 
al., 2011; Pascopella et al., 2014; Vasankari et al., 2007). 
A more severe state of TB infection, such as an infection affecting the central 
nervous system, disseminated or miliary disease, as well as coincidental pulmonary 
and extrapulmonary infection, increases the risk for death (Nguyen et al., 2011; 
Pascopella et al., 2014; Pradipta et al., 2018). Among pulmonary TB cases, cavitary 
disease and sputum smear positivity have been associated with both increased and 
decreased risk for death (Pascopella et al., 2014; Waitt et al., 2011). The former 
observation is probably due to a more severe state of disease and the latter due to 
enhanced diagnostic procedure. Furthermore, social risk factors, such as alcohol or 
drug abuse, unemployment and a low level of education, have been associated with 
the risk of death (Caylà et al., 2009; Pascopella et al., 2014; Sterling et al., 2006). 
Comorbidities are more common with increasing age. Chronic diseases, such as 
diabetes, chronic obstructive pulmonary disease (COPD), malignancies and severe 
renal insufficiency have been associated with death as outcome (Oursler et al., 2002; 
Waitt et al., 2011; Walpola et al., 2003). Furthermore, elderly patients often have 
many chronic diseases concomitantly. The combined effect of comorbidities, 
assessed using, e.g., the Charlson comorbidity index, on the risk of death among TB 
cases has very rarely been published (Fløe et al., 2018). A case-control register study 
from Denmark showed that mortality among TB cases was higher than among 
matched controls in all age groups above 20 years and comorbidities were associated 
with the risk of death among TB cases (Fløe et al., 2018).  
2.4.6 Risk factors for other non-successful outcomes 
Many studies using multivariable models have described male gender as a risk factor 
for unsatisfactory outcomes including outcomes lost to follow-up, failed and in some 
studies also former outcome category transferred out before or during TB treatment 
(Antoine et al., 2013; Holden et al., 2019; Stosic et al., 2020). Other published 
demographic risk factors include younger age and foreign origin, especially recent 
immigration (Antoine et al., 2013; Baussano et al., 2008; Pradipta et al., 2018). 
However, a study from Geneva, Switzerland, showed that asylum seekers had a 
higher probability for successful outcomes, but the group of unsuccessful outcomes 
also included a few cases with death as outcome (Kherad et al., 2009). 
Social risk factors, such as alcohol abuse, homelessness and being in prison have 
been associated with unsatisfactory outcomes (Baussano et al., 2008; Holden et al., 
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2019; Pradipta et al., 2018). Furthermore, diabetes, mental disorders and anaemia at 
the time of diagnosis have predicted unsatisfactory outcomes (Holden et al., 2019; 
Pradipta et al., 2018).  
The impact of the disease site is rarely published, because most studies evaluating 
risk factors for unsatisfactory outcomes have included solely pulmonary TB cases. A 
recent study from Serbia showed that having pulmonary TB increases the risk for 
outcome lost to follow-up (Stosic et al., 2020). Unsatisfactory outcomes have also 
been associated with cases having a history of former TB treatment (Antoine et al., 
2013; Stosic et al., 2020). A recent multinational European study also showed that 
isoniazid resistance predicts non-successful outcomes, including all other outcomes 
except successful (Karo et al., 2019). Being infected with MDR isolate has also been 
associated with the risk for non-successful outcomes (Antoine et al., 2007; Karo et 
al., 2015). 
Finally, a cohort study from Finland evaluating treatment regimens and duration 
showed that pause(s) in treatment and treatment regimen including ethambutol 
or/and streptomycin instead of pyrazinamide during the intensive phase were 
associated with an unsatisfactory outcome (Vasankari et al., 2007).  
2.5 Recurrent tuberculosis  
Recurrent tuberculosis means that a patient, after being treated for tuberculosis, gets 
the diseases again. Recurrence of TB increases the global burden of TB considerably. 
According to WHO, almost half a million recurrent TB episodes were notified in 
2015 representing almost 8% of all notified TB cases worldwide (WHO, 2017a). 
TB recurrence can occur in two ways: as re-infection and as relapse. Re-infection 
means that a person gets a new infection with a new strain of M. tuberculosis after 
being treated for tuberculosis. Relapse is due to endogenous reactivation with the 
same strain of M. tuberculosis as in the former TB episode.  
Definitions made by WHO distinguish retreatment cases from new cases of TB 
by the case having received at least one month of TB medication in the past (WHO, 
2014). Retreatment cases are further classified by the outcome of the preceding TB 
episode to relapses (successfully treated), treatment after failure, treatment after lost 
to follow-up and other previously treated patients (treatment outcome not known). 
WHO’s definition for relapse thus also includes recurrent cases due to re-infection. 
This definition may be appropriate for countries with low resources and a high 
incidence of TB. High-income countries, where relapses can be distinguished from 
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re-infections using genotyping methods when isolates from both TB episodes are 
available, restrict the use of the term relapse to cases due to endogenous reactivation 
(Rosser et al., 2018). The term recurrent TB is used instead. All the data presented 
in this section are from studies concerning low TB-incidence countries, if not 
mentioned otherwise.   
2.5.1 Definitions used in and inclusion criteria for studies of recurrent TB 
The definitions used for recurrent TB in studies are heterogeneous. Table 2 presents 
characteristics and inclusion criteria for a selection of studies from countries with a 
low TB incidence. Notified completion of TB treatment in the preceding TB episode 
is necessitated in many studies (Dobler et al., 2009; Pettit et al., 2011; Schiroli et al., 
2015). However, in some studies, all cases with a re-notified episode of TB are 
included regardless of TB treatment given or outcome of the preceding episode 
(Crofts et al., 2010; Dale et al., 2017). A recurrent TB episode is defined in a few 
studies as a patient notifying a previous diagnosis of TB (Afshar et al., 2019; Kim et 
al., 2013)  
Furthermore, the earliest time point set for a recurrent episode varies. Some 
studies say that a recurrent TB episode can occur right after treatment for the 
preceding episode was completed (at the earliest 6 months after the notification of 
the preceding episode) (Bang et al., 2010; Pettit et al., 2011). In other studies, a 12-
month period is necessitated to exist between TB episodes (Crofts et al., 2010). Some 
studies from the US especially require a 12-month period following completion of 
TB treatment in the preceding episode (Interrante et al., 2015; Kim et al., 2016;  
Millet et al., 2009). These are called late recurrences (Interrante et al., 2015; 
Pascopella, Deriemer, Watt, & Flood, 2011). Studies also vary by the length of the 
study period, as presented in Table 2.  
 Inclusion criteria for study cases also vary widely. A positive culture for M. 
tuberculosis in both episodes is required in studies using genotyping. Few studies 
include only episodes with pulmonary TB (Millet et al., 2013; Pascopella et al., 2011), 
while most studies also include extrapulmonary TB cases. Many studies are 
retrospective and based on only register data (Crofts et al., 2010; Kim et al., 2016) or 
include also medical records review (Avery et al., 2015; Bang et al., 2010). There are 
also few prospective interventional studies (Jasmer et al., 2004). Very few studies 
include assessment of TB treatments given in the episode preceding recurrence 
(Pascopella et al., 2011; Selassie et al., 2005). 
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Table 2. Selection of studies evaluating the frequency of TB recurrence and distinguishing 
relapses from re-infections  
Author, 
year 
Country, 
TB 
incidence
/100 000  
Co-
hort 
size 
n 
Inclusion 
criteria 
Recur-
rences 
n (%) 
Study 
period, 
years 
Incidence of 
recurrence/ 
100 000  
patient 
years 
Genoty-
ping 
performed 
for both 
isolates 
n/recurren
t cases n 
(%) 
Relapse 
n (%) 
Method 
Parvaresh 
2018 
Australia 
(New South 
Wales)  
3700 Culture +, 
12 months 
between TB 
episodes,  
treatment 
completed 
DOT for all 
18 
(0.5%) 
10  NA 15/18 (83%) 13 (87%) WGS 
MIRU-
VNTR 
Dale  
2017 
Australia, 
(Victoria) 
6.7 
4766 ≥2 TB episodes 
during study 
period 
irrespective of 
treatment 
outcome 
32 
(0.7%) 
13 NA 20/32 (63%) 18 (90%) MIRU-
VNTR 
Interrante 
2015 
USA 
9.7 
 
312589 Culture+, 
treatment 
completed 
+1 year 
3039 
(1.0%) 
19 NA 136/3039 
(4.5%) 
116 
(85.3%) 
RFLP, 
spoligot.  
Schiroli 
2015 
Italy 
9.5 
4682 Culture+, 
treatment 
completed 
83 
(1.8%) 
15 NA 83/83 (100%) 64 (77%) spoligot., 
MIRU-
VNTR 
Pettit  
2011 
USA 
5.8 
1431 Treatment 
completed 
20 
(1.4%) 
7 NA 15/20 (75%) 12 (80%) RFLP,  
for cases 
with <6 
bands  
spoligot., 
MIRU-
VNTR 
Bang 
 2010 
Denmark  
6.9-10.5 
4154 Culture+,  
treatment 
completed for 
relapses, 
irrespective of 
outcome for re-
infections 
73 
(1.8%) 
13.5 NA 73/73 (100%) 54 (74%) RFLP 
Dobler 
2009 
 
Australia 
(New South 
Wales) 
6.5 
3731 Culture +, 
treatment 
completed  
DOT for all 
15 
(0.4%) 
13 71 15/15 (100%) 11 (73%) spoligot. 
MIRU-
VNTR if 
identical 
isolates 
RFLP 
Kim 
2016 
USA 
9.7 
142221 Treatment 
completed,  
+1 year 
1714 
(1.2%) 
13 NA NA NA NA 
Pascopell 
2011 
USA 
(California) 
9.7 
23517 Culture+, 
pulmonary TB, 
treatment 
completed +1 
year 
148 
(0.6%) 
. 
15 NA NA NA NA 
Crofts 
2010 
England 
and Wales 
10.9 
53 214 12 months 
between TB 
episodes 
irrespective of 
treatment 
outcome  
588 
(1.1%) 
8 410 NA NA NA 
Modified from Rosser et al. 2018. WGS= whole genome sequencing, RFLP=IS6110RFLP, spoligot=spoligotyping 
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2.5.2 Frequency and incidence of recurrent TB 
Comparison between studies is challenging due to varying study protocols. A recent 
state-of-the-art article reported that the overall proportion of recurrent TB cases 
following treatment completion of the preceding TB episode was 3.4 % (range 0.4%-
16.7%) (Rosser et al., 2018). However, this article with 42 studies included studies 
from countries with a wide variation of TB-incidence (1.5-86/100 000). Five studies 
with only MDR cases were also included. Recurrence rates have varied from 0.4%  
up to 6.0% in studies from countries with low TB incidence (Dobler et al., 2009; 
Jasmer et al., 2004). The former was a retrospective cohort study from one Australian 
state with DOT for all TB cases. The latter was a prospective clinical trial with high- 
dose isoniazid and rifamycin administered with DOT twice or once a week during 
the continuation phase, and the study included a remarkable proportion of HIV-
positive cases.  
Several studies have demonstrated that the majority of recurrences occur during 
the first years of follow-up (Crofts et al., 2010; Dobler et al., 2009). The state-of-the- 
art article just mentioned reported that the median time to recurrence following 
completion of treatment of the preceding episode, estimated in 10 studies, was 1.4 
years (IQR 1.1.-2.8) (Rosser et al., 2018). As a result of a wide variety of TB 
incidences, lengths of study periods and study protocols, a comparable way of 
evaluating rates of TB recurrence between countries would be to calculate the 
incidence of recurrent TB/100 000 patient years of follow-up in the cohort and to 
compare it with overall incidence of TB in the country. The incidence of recurrent 
TB has been published in only few studies from countries with TB-
incidence<50/100 000 (Rosser et al., 2018). After excluding studies with mainly 
HIV-positive cases, the incidence of recurrent TB varies between 71/100 000 in 
New South Wales, Australia and 530/100 000 patient years in Madrid, Spain (Dobler 
et al., 2009; Millet et al., 2009). When these incidences are compared to overall TB 
incidences of the countries in question, the incidence of recurrent TB is 12-38 times 
higher (Crofts et al., 2010; Dobler et al., 2009).  
A distinct way to evaluate the period with the highest risk of TB recurrence would 
be to calculate the incidence of recurrent TB separately for subsequent years of 
follow-up in the cohort. This is particularly important in countries with a high 
proportion of elderly cases resulting in a higher reduction of cases in follow-up due 
to deaths during follow-up. However, as far as we know, this has not been published 
previously.  
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2.5.3 Rates of relapses and re-infections among recurrent cases 
Distinguishing relapses from re-infections is important, because they point out 
different challenges in TB control. Relapses reflect shortcomings in TB treatment 
programs, whereas re-infections reflect the epidemiologic situation in the country 
(Millet et al., 2013). M. tuberculosis isolates from both TB episodes need to be available 
for genotyping to distinguish relapses from re-infections. Isolates with identical or 
nearly identical genotypes are regarded as relapses and isolates with differing 
genotypes as re-infections (Bang et al., 2010; van Rie et al., 1999) The main attribute 
of the rate of re-infections is the incidence of tuberculosis in the population (Uys et 
al., 2009). The proportion of re-infections among recurrent cases with treatment 
completed in the preceding episode has been rated up to 75% in countries with high 
TB-incidence (van Rie et al., 1999). This study from South Africa was one of the 
earliest studies using genotyping to distinguish relapses from re-infections.  
Most recurrences are due to relapses in countries with low TB incidence (Rosser 
et al., 2018). The proportion of cases with relapses varies between 73-90% (Dale et 
al., 2017; Dobler et al., 2009). However, re-infections may play a more important 
role in certain subpopulations. A study from the US reported that re-infection was 
10-times more common as a cause of recurrence among Mexican-born immigrants 
than among natives (Interrante et al., 2015).  
The results just described are from studies using traditional genotyping methods. 
These methods may erroneously classify re-infections as relapses when the strains 
are genetically highly related. Whole genome sequencing has been proven to 
discriminate strains with higher sensitivity during the last few years (Nikolayevskyy 
et al., 2019). The first studies for recurrent TB using WGS in addition to traditional 
genotyping methods were from countries with a high TB incidence and had very 
short study periods (Bryant et al., 2013; Guerra-Assuncao et al., 2015). They showed 
a clear polarisation of the number of SNPs between isolates of subsequent TB 
episodes to 0-8, regarded as relapses, and to >100, regarded as re-infections. Later 
studies have shown that isolates with 8-30 SNP difference cannot be reliably 
classified as relapse or re-infection (Folkvardsen et al., 2020; Parvaresh et al., 2018). 
Recent studies from Australia and Canada concluded that 13-17% of cases 
classified as relapses using traditional genotyping methods seemed to be due to re-
infections using WGS (Parvaresh et al., 2018; Tyler et al., 2017). Furthermore, the 
interpretation is even more unclear in settings with a higher TB incidence and with 
a high predominance of genetically close strains, because a re-infection due to a very 
similar strain results in a very low number of SNPs between episodes (Folkvardsen 
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et al., 2020; Nikolayevskyy et al., 2019). In addition to the very small number of 
published studies using WGS, factors affecting the number of SNPs among relapse 
cases, such as the adequacy of treatment, have not been studied. Thus, further studies 
are needed.  
2.5.4 Risk factors for TB recurrence 
Recurrence of TB is dependent on many factors, e.g., characteristics of the patient, 
TB treatment given, the strain of M. tuberculosis in the preceding episode and TB 
incidence in the population.  
2.5.4.1 Patient characteristics 
Male gender has been shown to increase the risk of recurrence up to 2-4 times, but 
this finding has been inconsistent (Hung et al., 2015; Millet et al., 2009; Pascopella 
et al., 2011). Data published on age groups with increased risk have been 
incompatible (Golub et al., 2008; Kim et al., 2016; Selassie et al., 2005). Several 
studies have shown that the risk of recurrence is higher among immigrants (Crofts 
et al., 2010; Interrante et al., 2015). A study from London established that this was 
due to increased rate of both re-infections and relapses (Afshar et al., 2019). 
However, natives have also been associated with a higher risk of TB recurrence in a 
study from California (Pascopella et al., 2011). 
HIV infection has been reported to increase the risk of recurrence in several 
studies (Crofts et al., 2010; Driver et al., 2001; Unis et al., 2014). Golub et al. showed 
that the use of antiretroviral therapy decreases the risk of recurrence by half among 
HIV-positive TB cases (Golub et al., 2008). Studies from countries with high TB 
incidences have shown that the increased risk of TB recurrence among HIV-positive 
patients is due to re-infections, not relapses (Crampin et al., 2010; Sonnenberg et al., 
2002). This was also supported by one study from the US (Pettit et al., 2011).  
Furthermore, other diseases or medications that also impair the immune system 
may increase the risk of recurrence. An association between diabetes mellitus and 
TB recurrence has been published (Driver et al., 2001; Lee et al., 2014). Chronic lung 
disease, including COPD, asthma and interstitial lung diseases, has been shown to 
increase the risk of TB recurrence (Hung et al., 2015; Pettit et al., 2011). Hung et al. 
published that the increased risk was independent of smoking status, whereas Pettit 
et al. found an interaction between smoking and lung disease in the risk of recurrence 
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(Hung et al., 2015; Pettit et al., 2011). Smoking, per se, has also been associated with 
recurrent TB (Leung et al., 2015; Thomas et al., 2005). 
A history of alcohol and drug abuse has been reported as a risk factor for TB 
recurrence (Driver et al., 2001; Kim et al., 2016; Millet et al., 2009; Selassie et al., 
2005). A small study published by Cacho et al. showed that substance abuse increases 
the risk of relapses, not re-infections (Cacho et al., 2007). An interaction between 
poor treatment adherence and alcoholism has been published, which may, at least in 
part, explain the increased risk of relapse (Selassie et al., 2005). However, persons 
with substance abuse may also be more prone to become re-infected due to repeated 
exposure to TB and probably due to an impaired immune system. Other factors 
reflecting low social-economic status, e.g., unemployment and belonging to the 
lowest salary group have also been associated with recurrence (Anaam et al. 2012; El 
Sahly et al., 2004; Hung et al., 2015). It has been stated that the higher risk for 
recurrence among men might reflect other confounding risk factors more prevalent 
in men, such as smoking and alcohol abuse (Hung et al., 2015). 
2.5.4.2 Characteristics and treatment of TB episodes preceding recurrence 
Several factors concerning TB episodes preceding recurrence have been associated 
with recurrence, such as pulmonary TB as well as concomitant pulmonary and 
extrapulmonary TB (Crofts et al., 2010; Kim et al., 2016; Millet et al., 2009). A 
positive sputum culture at two months of treatment, cavitation at the time of 
diagnosis and residual cavitation at the end of TB treatment have been associated 
with recurrence in older studies with non-standard treatments (Aber et al., 1978; 
Benator et al., 2002; Mallory et al., 2000). In addition to reflecting more advanced 
disease at the time of diagnosis, persistent sputum culture positivity and residual 
cavitation may also result from inadequate treatment. Studies using genotyping have 
shown that recurrence among more advanced states of disease, such as pulmonary 
TB with cavities, miliary TB and TB affecting the central nervous system, is due to 
relapses (Bang et al., 2010; Cacho et al., 2007; Jasmer et al., 2004)  
A few studies have analysed the effects of treatment regimens and supervision of 
treatment in the preceding episode. A study from South Carolina reported that the 
treatment regimen not containing rifampicin increased the risk of recurrence by 9-
times, even when the duration of treatment with isoniazid+1-3 other anti-TB drugs 
was prolonged to 18-24 months (Selassie et al., 2005). In addition, a treatment 
regimen containing rifampicin only during the intensive phase and a treatment 
regimen containing only rifampicin and isoniazid without a third anti-TB drug during 
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the intensive phase have been shown to increase the risk of recurrence (Menzies et 
al., 2009; Pascopella et al., 2011). 
Furthermore, an association between poor treatment adherence and the 
recurrence of TB has been shown (Cox et al., Drier et al., 2001; Selassie et al., 2005). 
Selassie et al. found an interaction between prolonged treatment duration and poor 
treatment adherence for all treatment regimen groups (Selassie et al., 2005). 
Conflicting results have been published concerning the effect of supervision of TB 
treatment to lower the risk for recurrence (El Sahly et al., 2004; Kim et al., 2016).  
2.5.4.3 The phenotype of M. tuberculosis isolate in the preceding TB episode 
Finally, the phenotype of M. tuberculosis isolate may also affect the risk of recurrence. 
Isolates with resistance to at least one TB drug, and particularly isolates with 
resistance to pyrazinamide, have been associated with TB recurrence (Brugueras et 
al., 2020; Pascopella et al., 2011). These findings may be due to shortcomings in 
altering treatment regimens and duration for cases with drug resistance. Conversely, 
Jasmer et al. reported that isoniazid mono-resistance protects from TB recurrence, 
which may reflect intensified treatment when resistance is recognised (Jasmer et al., 
2004). Studies from countries with higher proportions of MDR cases have shown 
that being infected with an MDR isolate, and in particular being infected with pre-
XDR and XDR isolates, increases the risk of recurrence (Blöndal et al. 2012; Sun et 
al. 2017). Furthermore, M. tuberculosis isolates belonging to the Beijing genotype have 
been associated with relapses in studies from the US and Vietnam (Burman et al., 
2009; Huyen et al., 2013). Multidrug resistance is more prevalent among isolates with 
the Beijing genotype, but drug resistance was not related to this finding. 
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3 AIMS OF THE STUDY 
This thesis was carried out to evaluate the quality of tuberculosis treatment in Finland 
by assessing treatment outcomes at one year and recurrence of tuberculosis in a 
longer period and to determine risk factors for non-successful treatment. 
 
The specific aims were: 
1. to describe treatment outcomes notified for microbiologically confirmed 
pulmonary TB cases (Study I) 
2. to assess the frequency of recurrent TB (Study II) 
3. to distinguish relapses, which reflect insufficient treatment in the TB episode 
preceding TB recurrence, from re-infections among recurrent cases by using 
genotyping methods (Study III) 
4. to study risk factors for non-successful treatment by assessing risk factors for 
non-successful treatment outcomes and recurrent TB (Studies I and II) 
5. to evaluate the validity of treatment outcomes notified and the adequacy of 
TB treatments prescribed in the episode preceding recurrence (Studies I and 
II) 
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4 MATERIALS AND METHODS 
This dissertation is based on three articles. Studies I and II are retrospective cohort 
studies based on tuberculosis cases registered in the National Infectious Disease 
Register (TTR) in 2007-2014 and 1995-2013, respectively. Study III constituted a 
subpopulation of study II. Table 3 presents the study populations and data sources 
for studies I, II and III.  
 
Table 3. Data sources for studies I, II and III  
 Cohort Study 
population 
Subjects 
(n)  
National 
infectious 
disease 
register 
Medical 
records 
Finnish 
hospital 
discharge 
register 
Cause 
of death 
register 
Genotyping 
I Pulmonary 
tuberculosis 
cases 
registered in 
TTR in 2007-
2014 
Microbiologically 
confirmed 
pulmonary TB 
cases 
1416 Yes For cases 
with 
unsatisfactory 
outcomes 
(n=50) 
Yes Yes No 
II Tuberculosis 
cases 
registered in 
TTR in 1995-
2013 
Recurrent 
tuberculosis 
cases: ≥2 TB 
episodes 
registered in 
TTR during 
1995-2013 
50 Yes Yes No No No 
III Tuberculosis 
cases 
registered in 
TTR in 1995-
2013 
Recurrent TB 
cases with M. 
tuberculosis 
isolates 
available for 
genotyping from 
two episodes  
21 Yes Yes  No No Spoligotyping: 
For all 
isolates  
WGS: 
For isolates 
with identical 
spoligotypes 
in both 
episodes  
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4.1 Study protocols  
4.1.1  Study I 
All pulmonary TB cases registered in TTR during 2007-2014 were retrieved 
(n=1785). TTR is maintained at the Finnish Institute for Health and Welfare (THL). 
Cases with errors in registration (27), TB diagnosed outside Finland (8) and one TB 
episode registered twice (2) were excluded after assessing data in TTR. Cases with 
only clinical diagnosis with a decision to give TB treatment (306), for which 
treatment outcomes were not collected by TTR during the study period, and cases 
with MDR isolates (25), for which treatment outcomes are recommended by 
ECDC/WHO to be notified at 24 moths, were also excluded. All data in TTR were 
collected for the remaining 1416 study cases. Comorbidity data from the Finnish 
Hospital Discharge Register (HILMO), maintained by THL, were also collected to 
evaluate the impact of comorbidities on the risk of death.  
For cases with death as outcome, the structured data on the causes of death from 
the Cause of death register, maintained at the Statistics Finland, were collected to 
evaluate whether deaths were registered as TB related.  
Medical records were reviewed, when necessary, for cases with outcomes failed, 
lost to follow-up and notified as not known, to evaluate the reason for and adequacy 
of the outcome notified. 
4.1.2 Study II  
The study cohort included all TB cases registered in TTR during 1995-2013 
(n=8084). A case with recurrent TB was defined as one patient registered in TTR 
with at least two episodes of TB at least 360 days apart (n=84). Cases with errors in 
registration (13), laboratory contamination (1), no culture positivity in either episode 
(1), TB treatment given for <1 month or treatment outcome failed in the first 
episode (5) and only one long continuous TB episode (14), were excluded after 
assessing the data in TTR and medical records. All data in TTR and medical records 
were collected for the remaining 50 recurrent cases.  
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4.1.3 Study III 
Study III constituted a subpopulation of study II. Section 4.1.2 describes the study 
cohort, definition for recurrent TB cases and exclusion criteria with two exceptions: 
patients not receiving TB treatment in the first episode (3) were not excluded from 
study III while cases with only one culture-positive TB episode were excluded (6) 
from study III. Among the 42 patients with more than one culture-positive TB 
episodes during the study period, isolates from two TB episodes were available for 
21 patients. Every tenth M tuberculosis isolate was stored frozen before year 2000 and 
all isolates since 2000. Spoligotyping was performed for the isolates of these 21 
patients. Whole genome sequencing was performed for the isolates when 
spoligotypes in the two isolates were non-identical (n=18).  
4.2 Register data  
4.2.1 National infectious disease register data (Studies I, II, III) 
The National Infectious Diseases Register is maintained in Finland by THL for 
prevention and control of communicable diseases, based on Communicable Disease 
Act (Ministry of Social Affairs and Health, 2016). TTR collects data on TB cases 
from the treating physician and clinical laboratory of the hospital district in which 
the patient is diagnosed and treated, from the mycobacterial reference laboratory at 
THL and from the national population register. Data from different sources are 
connected as a case using the unique identifier or, when it is absent (recent 
immigrants and newborns), using the name and date of birth.  
Notifying TB cases to TTR is mandatory for physicians and laboratories. 
Laboratories notify positive culture and nucleic acid amplification test (NAAT) 
results for M tuberculosis (Kansanterveyslaitos, 2008). Since 2001, all laboratories have 
sent M tuberculosis isolates to the mycobacterial reference laboratory at THL for 
species confirmation, drug susceptible testing and genotyping. For physicians, it has 
been obligatory to notify TB cases with a positive culture, sputum smear or histology 
since 1995 and to notify clinically diagnosed TB cases with a decision to give full TB 
treatment since 2007 (Hulkko et al., 2010) . 
The registration date in TTR is the date when the first positive culture or NAAT 
sample is taken or, if these are absent, the date of the physician's notification. A case 
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is registered as pulmonary TB when (1) sputum culture or NAAT is positive for M. 
tuberculosis or (2) the physician’s notification includes an ICD10-code for pulmonary 
TB, a remark of pulmonary TB or a positive sputum smear microscopy result. All 
TB notifications for the same patient are combined as a case when the dates of 
notifications are within 12 months for non-MDR cases and within 36 months for 
MDR cases. 
Drug resistance and genotyping data are obtained from mycobacterial reference 
laboratory and data on positive HIV test results by connecting data in TTR. The 
country of birth and date of death are retrieved from the national population register. 
Table 4 details the information collected in TTR from different sources.  
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Table 4. Data sources for TTR and notified data on tuberculosis cases 
 
¹notified for cases registered in 2007-2014 
 
Variable Physician 
notification 
Clinical 
laboratory 
notification 
Mycobacterial 
reference laboratory  
Treatment 
outcome 
notification 
Population 
register 
name x x x x  
unique identifier  x x x x x (a must) 
gender x x x x¹ x 
place of residence x    x 
nationality x    x 
country of birth x    x 
date of death     x 
ICD-10 code x   x¹  
primary culture result  x    
NAA-test result  x    
sample type for the positive finding 
(culture or NAAT) 
 x    
sample date (culture or NAAT)  x    
treatment organisation in which 
positive sample taken 
 x    
histological diagnosis x     
sputum smear result 
(positive/negative) 
x     
isolate species confirmation   x   
isolate drug susceptibility   x   
isolate genotype   x   
a history of earlier TB diagnosis 
(since 1950) 
x     
in which year was earlier TB 
diagnosed 
x     
was TB treatment given for > 1 month 
in the earlier TB episode 
x     
was full treatment given in the earlier 
TB episode 
x     
has the decision been made to give 
full TB treatment in the current 
episode 
x     
date of TB treatment commencement    x¹  
date of TB treatment cessation    x¹  
total duration of treatment 
interruptions (days) 
   x¹  
INH and RIF concomitantly given 
(months) 
   x¹  
who decided to stop treatment    x¹  
treatment outcome     x  
patient transferred before cessation of 
treatment 
   x¹  
date and receiving hospital 
district/city/country  
   x¹  
additional information x x  x  
notifier information x x x x¹  
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4.2.1.1 Data on treatment outcomes in TTR (Study I) 
Notifying treatment outcomes and data on a given TB treatment for pulmonary TB 
cases with a positive culture, NAAT or sputum smear result has been compulsory 
for hospital districts since 2007. Treatment outcome categories are based on 
recommendations by WHO/IUATLD and ECDC/WHO regional office for 
Europe and are the following: cured, treatment completed, failed, lost to follow-up, 
died, still on treatment and not known (including transferred out cases) 
(ECDC/WHO regional office for Europe, 2009; Veen et al., 1998). Table 1 shows 
the definitions for these outcomes. TTR recommends outcomes in Finland to be 
evaluated by one physician in each hospital district. Table 4 shows data collected in 
TTR from treatment outcome notifications until year 2015.  
4.2.2 Finnish hospital discharge register data (Study I) 
Hospitals are required to collect and send patient information to HILMO for 
inpatients and outpatients, including name and unique identifier, diagnoses, 
admission and discharge dates; this has been maintained by THL with current 
information for hospital patients since 1995 (Terveyden ja hyvinvoinnin laitos, 
2012). All diagnoses in HILMO for study cases were retrieved three years preceding 
and one year following TB diagnosis to evaluate the impact of comorbidities on the 
risk of death. Data were not available for 132 cases with an incorrect or temporary 
unique identifier.  
4.2.3 Causes of death register data (Study I) 
The structured data on the causes of death from the Cause of death register, 
maintained at the Statistics Finland, was collected to define whether death was 
registered as TB related. Death was classified as TB related in this study for cases 
with TB as the immediate or underlying cause of death or as a significant condition 
contributing to death.  
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4.3 Medical records data  
4.3.1 Study I 
Medical records data were obtained for those patients with outcomes failed, lost to 
follow-up and notified as not known, for whom the reason for the notified outcome 
was not mentioned or was unclear in the outcome notification (n=12). Only the 
reason for and adequacy of the notified outcome were assessed from patient records.  
4.3.2 Studies II and III 
Data from medical records were obtained for the 84 patients registered in TTR at 
least twice during the study period, as described in section 4.1.2. All medical records 
for at least 6 months preceding and 18 months following TB episodes were ordered 
from hospital districts. Exclusion of cases without a true recurrent TB episode was 
assessed by the primary investigator and one other TB expert in the study group. 
The data collected from medical records for the 50 recurrent cases were 
demographics, pulmonary/extrapulmonary disease manifestations, radiological, 
microbiological, histological and laboratory, including HIV, test results, 
comorbidities, the use of immunosuppressive medication and substance abuse. 
Prescribed TB treatments and adverse events for the first TB episodes were also 
collected in detail, as well as application of directly observed treatment. Medical 
records for two study cases were not received.  
4.4 Categorisation of treatment outcomes (Study I) 
Outcomes were combined into 4 categories to evaluate risk factors for non-
successful treatment outcomes. Successful treatment outcome consisted of cases 
with outcomes cured and treatment completed. Unsatisfactory outcomes included 
cases with outcomes failed, lost to follow-up and not known. Cases with non-defined 
outcomes were either still on treatment at 12 months or the outcome was not 
notified to TTR. Outcome died included fatal cases. Treatment outcome 
categorisation for each case was based on the original outcome notified.  
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4.5 Categorisation of comorbidities (Study I) 
A model invented by Charlson et al. and modified by Deyo et al. was used to calculate 
comorbidity scores for chronic diseases to evaluate the impact of comorbidities on 
the risk of death (Charlson et al., 1987; Deyo et al., 1992). The model includes 17 
diagnostic groups for chronic diseases with an index weighted for severity of 
diseases. The index has been shown to be associated with 1-year mortality and can 
be used with register data and ICD-10 codes (Quan et al., 2011). The Charlson 
indexes were categorised into 4 groups: index 0 (no comorbidities), index 1-2, index 
3-4 and index ≥5, for this study. 
4.6 Categorisation of treatment regimens and durations (Study 
II)  
Described treatment regimens were categorised into four groups to evaluate 
adequacy of TB treatments given in TB episodes preceding recurrent TB (Table 5). 
The criteria used for adequate duration of treatment for standard treatment groups 
1 and 2 were based on an earlier publication (Vasankari et al., 2007). Adequacy of 
treatment regimens and durations for treatment groups 3 and 4 were assessed 
individually by the primary investigator and one other TB expert in the study group. 
Treatment outcomes for TB episodes preceding recurrence were defined by the same 
two experts using the criteria described earlier (section 4.2.1.1). 
 
Table 5. Criteria for evaluation of adequacy of treatment regimen and duration 
Treatment group Treatment regimen in 
intensive phase 
Treatment regimen in 
continuation phase 
Adequate duration of 
treatment 
Group 1 INH, RMP, PZA¹ INH, RMP ≥5.5 months 
Group 2 INH, RMP, EMB¹ (Group 
2) 
INH, RMP ≥8 months 
Group 3 Other probably effective 
combination of drugs² 
(Group 3) 
NA NA 
Group 4 Probably ineffective 
combination of drugs² 
(Group 4) 
NA NA 
INH=isoniazid, RMP=rifampicin, PZA=pyrazinamide, EMB=ethambutol 
¹±an additional TB drug 
²adequacy assessed by two experts of the study group 
NA=not applicable 
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4.7 Genotyping methods (Study III) 
Stored isolates were cultivated on Löwenstein–Jensen medium in order to receive a 
pure culture for genotyping. A commercially available kit (Isogen Bioscience BV, 
Maarssen, The Netherlands) was used to perform spoligotyping. The spoligotyping 
results were compared to the SITVIT2 database of the Institute Pasteur of 
Guadeloupe. Isolates with non-identical spoligotypes in the two episodes were 
stored frozen and re-cultured on 7H11 agar plates. A DNeasy blood and Tissue kit 
(Qiagen, Hilden, Germany) was used to isolate Genomic DNA for whole genome 
sequencing. Nextera XT kit (Illumina, San Diego, CA, USA) was used to prepare 
paired-end multiplex libraries and MiSeq platform (Illumina) to sequence the 
libraries. Single nucleotide polymorphisms (SNPs) in difficult to map regions 
(especially in annotated repeat regions) were excluded after processing sequence 
reads. Custom scripts were used to extract variant sites passing quality filters and 
SNP distances were determined between isolates.  
4.8 Statistical methods 
Statistical analyses were performed using the IBM SPSS Statistics for Windows, 
versions 22.0 and 25.0 (Armonk, NY: IBM Corp.) and StataCorp. 2015 (Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP). For categorical 
variables Chi-squared test and Fisher’s exact test were used, when appropriate. 
Mann-Whitney U-test was used for continuous variables with non-normal 
distribution. The cut point for a statistically significant p-value was set at <0.05.  
In study I, multinomial logistic regression model was used to estimate relative risk 
ratios (RRR) with 95% confidence intervals (95% CI) for non-successful outcome 
groups (died, unsatisfactory and non-defined) compared to the successful outcome 
group for potential risk factors with data available for the cohort, e.g., gender (males 
compared to females) and age as a continuous variable. Variables with p<0.20 in the 
univariate analysis were included in multivariable analysis. Multi-imputation with 
MICE-algorithm was used for missing data of variables drug resistance, sputum 
smear microscopy and the Charlson comorbidity index (van Buuren, 2007). Akaike 
information criteria with backward selection were used to obtain the most 
parsimonious model, its explanatory variables and their appropriate interactions 
(Akaike, 1974).  
 
49 
In study II, a follow-up time from 360 days after notification date in TTR until 
re-notification (recurrent episode of TB), death or the end of the study period, was 
calculated individually for all cases in the cohort. The incidence of recurrent TB was 
calculated as the number of recurrent episodes/the sum of follow-up years in the 
cohort and described as the number of recurrent episodes/100 000 follow-up years, 
separately for the first year, the second year and the overall follow-up time. Log-
linear regression model was used for the pseudo-observations, which were generated 
using cumulative incidence functions under competing risks (Parner et al., 2010). 
Risk ratios (RR) with 95% CI for potential risk factors with data available for the 
cohort, e.g., gender (males compared to females) and age (at the registration date of 
the first episode) as a continuous variable, were estimated. Time dependent effects 
were allowed for variables gender and anatomical disease site 
(pulmonary/extrapulmonary TB) in the model. Variables with p<0.20 in the 
univariate analysis were included in multivariable analysis. 
4.9 Ethical considerations 
This is a retrospective cohort study without contact with patients. Therefore, 
approval by Ethics Committee and informed consent to participate was not required. 
Permission for collecting data from national registers and medical records was given 
by the National Institute for Health and Welfare. 
 
50 
5 RESULTS 
5.1 Treatment outcomes for microbiologically confirmed 
pulmonary TB cases (Study I) 
5.1.1 Characteristics of the cohort  
The final study cohort consisted of 1416 microbiologically confirmed pulmonary TB 
cases diagnosed in Finland during 2007-2014. Among the cases, 64.6% were males 
and 72.7% were of Finnish origin (Table 6). The foreign-born cases were 
significantly younger than the Finnish-born cases (median ages 28 years vs. 70 years, 
p<0.001). The median age of all cases was 60 years (range, 0-98 years). TB diagnosis 
was confirmed by positive culture for 1388 (98.0%), positive NAA-test result for 16 
(1.1%), and positive sputum smear and the treating physician’s intent to give full TB 
treatment for 12 (0.9%) cases. The proportions of fully susceptible, mono-resistant 
and poly-resistant isolates were 89.1%, 6.5% and 1.8%, respectively. Besides the 28 
culture negative cases, drug resistance results were not known for eight culture 
positive cases. Sputum smear was positive for 694 (49.0%) and not notified for 93 
(6.6%) cases. HIV positivity was notified for 25 cases (1.8%). Five cases (0.4%) were 
registered with two separate TB episodes during the study period. 
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Table 6. Characteristics of the cohort and risk factors for non-successful outcomes in univariate 
analysis 
Variable 
 
Category, n 
 
Successful 
(1063) 
n (%) 
 
Died 
(231) 
n (%) 
 
Univariate 
RRR¹ for 
death² 
(95% CI) 
p 
Unsatisfactory³ 
(50) 
n (%) 
Univariate RRR¹ 
for 
unsatisfactory² 
(95% CI) 
p 
Non-defined⁴ 
(72) 
n (%) 
Univariate 
RRR¹ for 
non-defined² 
(95% CI) 
p 
Age Age/10 years Median 57 
years 
Median 79 
years 
1.77  
(1.53-2.06) 
<0.001 
Median 27.5 years 0.65  
(0.59-0.72) 
<0.001 
Median 51.5 
years  
0.96 
(0.87-1.05) 
0.341 
Gender Female (501) 387 (77.2%) 68 (13.6%)  
 
1 17 
(3.4%) 
 
1 29 
(5.8%) 
1 
 Male (915) 676 (73.9%) 163 (17.8%) 
 
1.37 
(1.06-1.77) 
0.015 
33 
(3.6%) 
 
1.11 
(0.68-1.82) 
0.677 
43 
(4.7%) 
 
0.85 
(0.49-1.46) 
0.552 
Origin Finnish (1030) 744 (72.2%) 225 (21.8%) 
 
1 13 
(1.3%) 
 
1 48 
(4.7%) 
 
1 
 Foreign (386) 319 (82.6%) 6 (1.6%) 
 
0.06  
(0.04-0.11) 
<0.001 
37 
(9.6%) 
 
6.64 
(3.68-11.98) 
<0.001 
24 
(6.2%) 
 
1.17 
(0.70-1.93) 
0.551 
Drug 
resistance 
non-MDR⁵ 
No (1262) 966 (76.5%) 207 
(16.4%) 
 
1 38 
(3.0%) 
 
1 51 
(4.0%) 
 
1 
 Yes (118) 74  
(62.7%) 
12 
(10.2%) 
 
0.76  
(0.33-1.74) 
0.511 
12 
(10.2%) 
 
4.12 
(2.02-8.41) 
<0.001 
20 
(16.9%) 
 
5.12 
(3.23-8.11) 
<0.001 
Sputum 
smear⁶ 
Negative (629) 481 (76.5%) 96 
(15.3%) 
 
1 23 
(3.7%) 
 
1 29 
(4.6%) 
 
1 
 Positive (694) 527 (75.9%) 105 
(15.1%) 
 
0.998 
(0.82-1.21) 
0.986 
24 
(3.5%) 
 
0.95 
(0.48-1.87) 
0.888 
38 
(5.5%) 
 
1.20 
(0.80-1.79) 
0.387 
Study period 2007-2010 
(760) 
570 (75.0%) 118 
(15.5%) 
 
1 31 
(4.1%) 
 
1 41 
(5.4%) 
 
1 
 2011-2014 
(656) 
493 (75.2%) 113 
(17.2%) 
 
1.11 
(0.88-1.39) 
0.383 
19 
(2.9%) 
 
0.71 
(0.51-0.99) 
0.045 
31 
(4.7%) 
 
0.87 
(0.43-1.77) 
0.709 
Charlson 
comorbidity 
index⁷ 
0 (631) 550 (87.2%) 30 
(4.8%) 
 
1 
 
17 
(2.7%) 
 
1 
 
34 
(5.4%) 
 
1 
 1-2 (462) 322 (69.7%) 111 
(24.0%) 
 
6.32 
(4.57-8.74)  
<0.001 
9 
(2.0%) 
 
0.90 
(0.30-3.73) 
0.859 
20 
(4.3%) 
 
1.00 
(0.60-1.67) 
0.985 
 3-4 (172) 109 (63.4%) 54 (31.4%) 9.08  
(5.63-14.66) 
<0.001 
1 (0.6%) 0.30 
(0.04-2.36) 
0.251 
8 
(4.7%) 
 
1.19 
(0.50-2.82) 
0.697 
 ≥5 (85) 52 (61.2%) 28 (32.9%) 9.87  
(4.63-21.06) 
<0.001 
1 (1.2%) 0.62  
(0.11-3.67) 
0.600 
4 
(4.7%) 
1.24 
(0.55-2.79) 
0.596 
¹RRR=ratio of relative risks 
² compared to successfully treated cases  
³ including cases with outcomes failed, lost to follow-up (treatment interrupted) and not known (transferred out) 
⁴including cases with outcome still on treatment and cases without an outcome notification 
⁵Information missing for 36 cases (23 successfully treated cases, 12 fatal cases, 1 non-defined case)   
⁶Information missing for 93 cases (55 successfully treated cases, 30 fatal cases, 3 other defined unsuccessfully treated cases, 5 non-defined outcome) 
⁷Information missing for 66 cases (30 successfully treated cases, 8 fatal cases, 22 other defined unsuccessfully treated cases, 6 non-defined outcome) 
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5.1.2 Treatment outcomes 
Treatment outcome was notified as successful for 1063 (75.1%), as death for 231 
(16.3%), as unsatisfactory for 50 (3.5%) and as non-defined for 72 (5.1%) cases 
(Figure 1). Among the 50 unsatisfactory outcomes, outcome notified as not known 
was the main outcome with 35 (70%) cases, followed by outcome lost to follow-up 
with 12 (24%) and outcome failed with 3 (6%) cases. Treatment outcome was not 
notified for 20 (1.4%) cases, and 52 (3.7%) cases were still on treatment at twelve 
months after treatment initiation. 
 
 
Figure 1. Treatment outcome categories among study cases 
5.1.3 Duration of treatment 
Treatment duration was notified for 1204 (85.0%) cases, and median duration was 
204 days (interquartile range (IQR), 183-278 days). Treatment duration for cases 
notified with a successful outcome was analysed in detail to evaluate the validity of 
treatment outcome assessment in notifications (Table 7). The duration of treatment 
for 6 cases (0.6%) was too short (less than 5.5 months), and 91 cases (8.6%) received 
treatment for more than 12 months. Hence, treatment outcome assessment for cases 
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notified with a successful outcome was incorrect in 97 (9.2%) cases according to 
treatment durations notified. 
 
Table 7. Distribution of treatment durations for successfully treated and fatal cases 
Treatment duration Successful (n=1063) 
n (%) 
Died (n=231) 
n (%) 
No treatment 0 (0%) 58 (25.1%) 
Treatment duration <5.5 months 6 (0.6%) 137¹ (59.3%) 
Treatment duration 5.5-12 months 913 (85.9%) 12 (5.2%) 
Treatment duration >12 months 91 (8.6%) 1 (0.4%) 
Treatment duration not notified 53 (5.0%) 23 (10.0%) 
¹81 cases (35.1%) received treatment for <2 months 
5.1.4 Cases with death as outcome 
Death was notified as outcome for 225 cases (21.8%) among Finnish-born and for 
6 cases (1.6%) among foreign-born cases. Fatal cases were significantly older than 
cases with a successful outcome (median age 79 years (range 0-96) versus 57 years 
(range 0-98), p<0.001). Among cases with death as outcome, 25.1 % did not receive 
any TB medication and 35.1% received treatment for less than 2 months (early 
deaths with TB 60.2%) (Table 7). TB was not registered as a cause of death in death 
certificates for 64 (27.7%) of the fatal cases. Death was classified as TB related for 
the rest. TB was registered as the immediate/underlying cause and as a significant 
condition contributing to death in 101 (43.7%) and 64 (28.6%) cases, respectively. 
Cases classified with a TB-related death did not have significantly different Charlson 
comorbidity indexes than cases classified with a non-TB-related death (p=0.13). 
Among all cases with death as outcome, death was associated with Finnish origin, 
increasing Charlson comorbidity index, increasing age and male gender in univariate 
analysis (Table 6). These risk factors, except Finnish origin, were also predictors for 
death in the multivariable logistic regression model (Table 8). The risk for death 
among men was higher compared to women, but the risk ratio decreased with 
increasing age (interaction between gender and age). 
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Table 8. Risk factors for non-successful treatment outcomes and TB recurrence in multivariable 
models 
Risk factors  Death (n=231) 
RRR¹ (95% CI), p 
 
Unsatisfactory 
outcomes 
(n=50) 
RRR¹ (95% 
CI), p 
Non-defined 
outcomes  
(n=72) 
RRR¹ (95% CI), p 
TB recurrence 
(n=50) 
RR² (95% CI), p 
Age/+10 years 
 
Finnish male 1.5 (1.3-1.8), 
p<0.001 
Finnish female 1.9 (1.4-2.7), 
p<0.001 
Foreign origin male 1.2 (0.9-
1.6), p=0.18 
Foreign origin female 1.6 (1.04-
2.3), p=0.03 
0.6 (0.3-1.1), 
p=0.09 
0.9 (0.7-1.1), 
p=0.19 
0.8 (0.7-0.99), 
p=0.04 
Male gender 9.5 (1.4-66.7), p=0.02 1.4 (0.4-4.4), 
p=0.62 
1.2 (0.4-4.0), 
p=0.34 
5.9 (2.2.-15.7) 
p<0.001³ 
Charlson 
comorbidity 
index>0 
 
Charlson 1-2: 3.0 (2.1-4.4), 
p<0.001 
Charlson 3-4: 3.6 (2.2-5.8), 
p<0.001 
Charlson ≥5: 5.9 (2.7-13.3), 
p<0.001 
NA NA NA 
Drug resistance   0.8 (0.3-2.1), p=0.71 2.6 (1.2-5.8), 
p=0.02 
5.6 (3.8-8.1), 
p<0.001 
Data not 
analysed⁴  
Pulmonary TB NA NA NA 15.2 (5.0-46.1), 
p<0.001  
¹RRR=ratio of relative risks, compared to successfully treated cases 
²RR=relative risk, compared to cases with no recurrence 
 at 18 years of follow-up 
⁴5/50 recurrent cases (10%) had a drug-resistant isolate in the first episode (INH R) 
NA=not applicable 
Modified from Korhonen et al., 2017 
 
5.1.5 Cases with unsatisfactory outcomes 
Among the 50 cases with unsatisfactory outcomes, the reason for the notified 
outcome was available in outcome notifications for 38 cases, and medical records 
data were reviewed for the remaining 12 cases. Table 9 shows in detail the reasons 
and incorrectly assessed treatment outcomes. Risk factors in the univariate model 
for unsatisfactory outcomes were foreign origin, non-MDR drug resistance, younger 
age and TB registered in the first study period (Table 6). An interaction between 
origin and age was observed. In the multivariable model, an independent association 
was observed with non-MDR drug resistance (Table 8) and TB registered in the first 
study period (ratio of relative risks, (RRR) 1.5; 95%CI, 1.1-2.1, p=0.02). Restricting 
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analysis to outcomes notified as failed and lost to follow-up combined yielded non-
MDR drug resistance as a risk factor (univariate RRR, 4.8; 95% CI 2.1-11.0, p<0.001; 
multivariate RRR, 4.9; 95% CI 2.3-10.7, p<0.001) (data not shown). 
5.1.6 Cases with non-defined outcomes 
The reasons for prolonged treatment among the 52 cases with outcome still on 
treatment were notified for 36 cases (69%), shown in Table 9. The only risk factor 
associated with non-defined outcome was non-MDR drug resistance in univariate 
(Table 6) and multivariable regression analysis (Table 8). 
 
Table 9. Explanations for unsatisfactory and non-defined outcomes 
Notified outcome, n Explanation for correctly notified 
outcomes, n 
Incorrectly 
notified 
outcome¹,  
n (%) 
Correct outcome, n 
Failed 3 
 
Positive sputum culture at 5 months or later 
during treatment 2 
1 (33.3%) Treatment completed 1 
Lost to follow-up 12 Severe substance abuse 4 
Severe adverse reaction 3 
Positive culture missed by physician 1  
4 (33.3%) Not known 3 
Still on treatment 1 
Not known 35² 
 
 
Case transferred to another country 25³ 
Case disappeared 4³ 
Case transferred in Finland 3⁴ 
3 (8.6%) Still on treatment 1 
Treatment completed 1 
Lost to follow-up 1 
Still on treatment 52 Non-MDR drug-resistant isolate 19 
Miliary/disseminated disease 5 
Advanced cavitary disease 4 
Pauses on treatment 4 
Bone and joint tuberculosis 2  
Recurrent TB 1 
Prolonged sputum culture positivity 1 
Explanation not notified 16 
NA NA 
¹evaluation based on additional information in notifications and patient chart review  
²origins: 33 foreign, 2 Finnish  
³ before or during treatment 
⁴ and the final outcome not notified by the receiving hospital district 
NA=not applicable 
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5.2 Recurrent TB (Study II) 
5.2.1 The cohort  
There were 8084 tuberculosis cases registered in TTR during the study period of 
1995-2013. Among the cases, 57.1% were males and 84.6% of Finnish origin (Table 
10). Finnish-born cases were significantly older than cases with foreign origins 
(median ages 70 years versus 30 years, p<0.001).  
5.2.2 Characteristics of recurrent TB cases 
The study population consisted of 50 patients with at least two verified TB episodes 
at least 360 days apart. Two of these had 3 TB episodes and 48 had 2 TB episodes 
during the study period. Table 10 presents demographic data as well as data on some 
potential risk factors for recurrence. Pulmonary TB was significantly more common 
among males than females (97.4% vs 54.5%, p<0.001) in the first episode. Two cases 
were HIV positive among the 18 recurrent cases (36% of all) with HIV test result 
available on patient charts. In the first episode, 43 cases (86%) had a fully susceptible 
isolate, 5 cases (10%) were infected with an isoniazid-resistant isolate, and 2 cases 
(4%) were culture negative. Substance abuse, mostly alcohol, was registered in 
patient records for 23 (59%) males and for none of the females. Compliance with 
TB treatment could not be assessed, because this was rarely mentioned in patient 
records. 
 
In summary, treatment outcome was successful in 75% of cases and 16% 
of cases died with TB. Risk factors for death were male gender, 
comorbidities and increasing age. Drug resistance was a risk factor for non-
successful outcomes other than death. Notified treatment outcome was 
incorrect in 16% of cases notified with unsatisfactory outcomes and in 9% 
of cases notified with successful outcomes. 
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Table 10. Characteristics of recurrent TB cases and the whole cohort of TB cases in Finland 
1995-2013 
Characteristics TB recurrence (n=50) 
n (%) 
All (n=8084) 
n (%) 
Age, median 51.5 years¹ 66 years 
Gender male 39 (78.0%) 4616 (57.1%) 
Origin Finnish 41 (82.0%) 6838² (84.6%) 
Culture positive 48 (96.0%)¹ 6680 (82.6%) 
Pulmonary TB 44 (88.0%)¹ 5605 (69.3%) 
Study period 1995-2006 45 (90.0%)¹ 5807 (71.8%) 
¹data of the first TB episode during the study 
²origin not known for 172 cases  
Modified from Korhonen et al, 2017 
5.2.3 Treatment regimens and treatment outcomes for TB episodes 
preceding recurrence 
Adequacy of TB treatment could be evaluated for 48 cases (96%) with complete 
patient records (Table 11). The described treatment regimen was adequate for 42 
cases, but for 7 of these, the treatment period was too short. Treatment regimen was 
inadequate for 6 cases. Among the 35 cases with an adequate treatment regimen for 
long enough, treatment outcome was successful for 27, and 8 cases were still on 
treatment at 12 months. Among the 14 cases with outcome lost to follow-up, 
premature treatment cessation was due to the patient in two cases, due to the treating 
physician’s decision in 6 cases, and the treating physician had prescribed an 
inadequate treatment regimen in 6 cases. The treatment outcome was successful in 
27 (55%), lost to follow-up in 14 (29%) cases, and 8 (16%) cases were still on 
treatment at 12 months from treatment initiation. Successful treatment outcome was 
more common among males than females (61.5% vs 27.3%, p=0.04) and among 
pulmonary TB than extrapulmonary TB (59.1% vs 16.7%, p=0.05). Directly 
observed therapy was implemented for 6 cases (12%).  
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Table 11. Adequacy of treatment and evaluation of treatment outcomes for recurrent cases  
 Treatment period 
adequate 
Treatment period 
inadequate 
Treatment outcome 
Treatment regimen  
adequate 42 
35 7 Successful 27  
Still on treatment 8  
Lost to follow-up 7 
Treatment regimen 
inadequate 6 
NA NA Lost to follow-up 6 
Adequacy of 
treatment regimen 
not evaluated 1¹ 
NA 1¹ Lost to follow-up 1 
¹treatment outcome evaluated based on additional information on treatment outcome notification  
NA=not applicable 
5.2.4 Incidence of and risk factors for TB recurrence 
Median follow-up time among the cohort of 8084 TB cases was 6.1 years (IQR 2.7-
11.1 years). Maximal follow-up time was 18 years. Half of the recurrences among all 
cases and all recurrences among women and extrapulmonary cases occurred within 
the first 2 years of follow-up (Figure 2). The incidences for TB recurrence for the 
first year of follow-up, the second year of follow-up and for overall follow-up time 
were 236 (95%CI 140-399), 207 (95%CI 115-373) and 113 (95%CI 86-149) per 100 
000 person years, respectively. 
Older age decreased the risk of TB recurrence in univariate (RR/+10 years 0.9; 
95%CI 0.8-0.98, p=0.03) and multivariate analysis (Table 8). Male gender, compared 
to women, and pulmonary TB, compared to extrapulmonary TB, were not predictors 
for recurrence at 1 and 2 years of follow-up (Figure 2). However, at 18 years of 
follow-up TB recurrence was associated with male gender (RR 3.9; 95% CI 2.0-7.9, 
p<0.001) as well as pulmonary TB (RR 5.5; 95% CI 2.2-14.1, p<0.001) in univariate 
analysis. In multivariate analysis, male gender was an independent risk factor for 
recurrence with almost a six-fold risk ratio and pulmonary TB with a 15-fold risk 
ratio (Table 8). 
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Figure 2. Cumulative risk of recurrence of TB by follow-up time (and its 95% confidence limits).       
a. For overall cohort b. By gender c. By anatomical site of disease d. For culture positive 
cases only. Modified from Korhonen et al., 2017.  
5.2.5 Very early recurrences (data not published) 
Cases with re-notification in TTR by a physician or laboratory 6-12 months (183-
359 days) after the notification date of the first episode were retrieved to assess the 
number of very early recurrences, which are missed by our study protocol. Among 
these 22 cases, there were errors in notification dates in 9 cases, other registration 
errors in 2 cases, only 1 long continuous TB episode in 2 cases, and 1 case did not 
receive TB treatment in the first episode. One case had a true very early recurrence, 
because treatment outcome was notified as lost to follow-up for the first episode. 
The reason for re-notification for 9 cases with no additional information in NIDR 
could not be evaluated, because a patient chart review was not carried out.  
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5.3 Genotyping data for recurrent TB cases (Study III) 
Among the 42 patients with >1 culture-positive TB episodes during the study period 
of 1995-2013, isolates from two episodes were available for genotyping in 21 
patients. M. tuberculosis isolates from the first and second episodes had unidentical 
spoligotypes in 3 (14%) patients, meaning that TB recurrence was due to re-
infection. One of these patients was from Somalia and one from the former Soviet 
Union. The third patient’s origin was Finland, but a new TB contact before the 
recurrent TB episode was recognised according to a patient records review. Eighteen 
(86%) patients with M. tuberculosis isolates with identical spoligotype in both episodes 
were suspected of having relapse TB. 
5.3.1 Characteristics of cases with suspected relapse TB 
Among the cases, 68.7% were males and 83.3% were of Finnish origin. The mean 
age was 63 years (range, 25-95 years) at the first episode’s registration time. Based on 
drug-susceptible testing, two patients had isoniazid-resistant isolates in both 
episodes, but for one of them, the isolate was also resistant to streptomycin in the 
second isolate. One patient with a fully susceptible isolate in the first episode had a 
pyrazinamide-resistant isolate in the second episode. The interval between 
registration dates of TB episodes was 1-2 years in 9 (50%) cases, 2-4 years in 7 (39%) 
cases and >4 years in 2 (11%) cases. The treatment outcome in the first episode was 
successful in 10 (55.6%) cases, lost to follow-up in 4 (22.2%) cases and still on 
treatment in 3 (16.7%) cases. The treatment outcome could not be evaluated due to 
lacking patient records for one (5.6%) case.  
In summary, 0.6% of TB cases were recurrent in our study with a median 
follow-up time of 6 years in the cohort. Risk factors for TB recurrence were 
pulmonary TB, male gender and younger age. Among recurrent cases, 
treatment outcomes for TB episodes preceding recurrence were assessed as 
successful in 54%, lost to follow-up in 28% and still on treatment in 16% of 
cases. 
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5.3.2 Whole genome sequencing data of cases with identical spoligotypes 
in both episodes 
Whole genome sequencing was performed for M. tuberculosis isolates from both 
episodes in 18 patients suspected of having relapse TB. The median number of 
SNPs, i.e. mutations in base pairs, between isolates from two episodes of a same 
patient was 1 (IQR 0-5). This strongly suggests that TB recurrence in these cases was 
due to relapse, except for 1 outlier with 38 SNPs (Figure 3). Compared to the 
reference sequence (M. tuberculosis H37Rv), the first isolate of the outlier had 20 
unique SNPs and the second isolate had 18 unique SNPs. This infers that the second 
isolate did not evolve directly from the first, suggesting that the second episode was 
due to re-infection. When SNPs were calculated relative to the time interval between 
episodes, the median number of mutations per genome per year was 0.4 (IQR 0-2.5). 
The outlier had 17.3 SNPs/year, which also supports the idea of recurrence due to 
re-infection. The number of SNPs did not seem to be directly related to the interval 
between TB episodes or the first episode’s treatment outcome (Figure 3). 
 
 
 
Figure 3. Treatment outcome and number of years between TB episodes in relate to number of 
SNPs between isolates of the same patient. Modified from Korhonen et al., 2016 
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In summary, 14% of recurrent TB cases had unidentical spoligotypes in isolates 
from the first and the second episodes, meaning that recurrence was due to re-
infection. Whole genome sequencing was performed for both isolates from the 18 
patients suspected of having relapse TB. In 17/18 cases there were 0-6 mutations 
between isolates of a same patient strongly suggesting that recurrence was due to 
relapse. In 1 case, the number of SNPs was 38. It is probable, that this case had been 
re-infected by M. tuberculosis isolate with identical spoligotype with the isolate in the 
first episode. 
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6 DISCUSSION 
6.1 Study populations 
This dissertation included two national cohorts of TB cases registered in TTR. We 
had long retrospective study periods of eight (Study I) and 19 years (Studies II and 
III) to ensure adequate study populations because of the rather low annual number 
of TB cases registered in Finland. Study I presents treatment outcomes for 
microbiologically confirmed pulmonary TB cases, except for cases with MDR-
isolates. The notification rate is very high in Finland, with treatment outcomes 
notified for 99% of the cases. Treatment outcomes in Finland are not notified for 
extrapulmonary cases and are notified for pulmonary cases without a microbiological 
confirmation only since 2017. Most former studies also restrict outcome reporting 
to non-MDR pulmonary TB cases, whereas a few newer studies also report 
outcomes for extrapulmonary cases (Guthmann et al., 2020; Stosic et al., 2020). Our 
results cannot be generalised for extrapulmonary and MDR cases even though our 
cohort was large with 1416 cases.  
Studies II and III were based on the cohort of all notified TB cases during 19 
years consisting of 8084 cases. Our study period is among one of the longest, but 
due to the small number of TB cases diagnosed annually, the size of the cohort and 
the number of recurrent cases is average compared to other studies published (Table 
2).  
6.2 Non-successful treatment outcomes and recurrent TB 
The rate of successful treatment outcome in Finland, 75%, is far from the 85% target 
set by WHO, mostly because of a high 16% proportion of cases with death as 
outcome. However, the rate of cases with unsatisfactory outcomes, which have a 
potential to transmit the disease, is rather low, 3.5%. Recurrent TB cases are rare, 
constituting only 0.6% of all TB cases. More than 80% of recurrent cases are due to 
relapses.  
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6.2.1 Death as outcome 
Among pulmonary TB cases in Finland, death as outcome has decreased from 19% 
in the mid-1990s to current 16%, but the proportion is still remarkably higher than 
the overall 7% found in the 16 European Union/European Economic Area 
(EU/EEA) countries between 2002-2011 (Karo et al., 2015; Vasankari et al., 2007). 
Nevertheless, the proportion is in line with some other European countries, e.g., 
Czech Republic (18%) and Slovenia (14%), with somewhat similar demographics 
among TB patients (Karo et al., 2015). Comparison of death rates between countries 
with differing distributions of risk factors, such as the proportion of elderly cases 
and cases with comorbidities, is of limited value, because all deaths before or during 
TB treatment are notified irrespective of the cause of death. The mean age among 
Finnish-born TB cases is exceptionally high, such as 71 years in 2017, the highest 
among the EU/EEA countries (ECDC/WHO regional office for Europe, 2019).  
Our observation that almost two thirds of cases with death as outcome die early 
(before or during the first two months of treatment) is in line with two studies from 
the U.S. (Nguyen et al., 2011; Pascopella et al., 2014). Our observations of a high 
proportion of early deaths and a high proportion of comorbidities, together with 
earlier observations of more severe forms of TB resulting in death as outcome, 
indicate that many cases who die present at a state when their disease has already 
become difficult to treat (Pascopella et al., 2014; Pradipta et al., 2018). The diagnostic 
delays by the health-care system may be remarkable, in addition to delays in patients 
seeking care. A case-control study from the U.S. showed that TB-related deaths were 
associated with an alternative diagnosis, e.g., pneumonia, before the TB diagnosis 
(Beavers et al., 2018). Non-infective chronic comorbidities may also increase the risk 
for death not only as a cause of death but also due to causing delays in diagnostics 
by offering an alternative explanation for symptoms. 
As far as we know, our study was the first to compare the combined effect of 
comorbidities, using the Charlson comorbidity indexes, between cases with TB-
related and non-TB-related deaths categorised by the causes of death on death 
certificates. We did not find significant differences between these groups. This may 
be explained by the facts that assessing the impact of TB on death in patients with 
comorbidities is not always clear, and cases with early deaths may not have a 
confirmed TB diagnosis before death. A retrospective study from the U.S. 
categorised cases with death as outcome as having a TB-related or non-TB-related 
death by the study group performing an intensive medical records review (Beavers 
et al., 2018). They observed that the sensitivity and specificity of death certificate 
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data to detect TB-related deaths was only 55% and 75%, respectively, and the 
definition for TB-related death was similar to our definition. 
6.2.2 Other non-successful treatment outcomes  
Among cases with unsatisfactory outcomes, outcomes failed and lost to follow-up 
combined are rare in Finland with only a 1% proportion compared to the 8% 
proportion in the study of 16 EU/EEA countries between 2002-2011 (Karo et al., 
2015). However, the 2% proportion of cases notified as outcome not known, mainly 
because they transferred to another country before or during treatment, is higher 
than in many studies from high-income European countries  (Holden et al., 2019; 
Karo et al., 2015). These cases may have a potential to transmit the disease further if 
treatment is interrupted; thus, staying in Finland until treatment completion or 
continuation of treatment in the receiving country should be ensured. 
The main outcome among non-defined outcomes was still on treatment at 12 
months with almost a 4% proportion, which is slightly higher than the average 
proportion in the study of 16 EU/EEA countries between 2002-2011 (Karo et al., 
2015). Treatment outcome was not notified for only 1% of cases.  
6.2.3 Recurrent TB  
The proportion of recurrent TB cases in Finland, 0.6%, is in line with other studies 
from countries with low TB incidences (Table 2). However, differing study 
protocols, lengths of study periods and incidence of TB make comparisons less 
reliable. Unlike many other studies, we did not include cases with very early 
recurrences (in 6-12 months after the notification date of the first episode), because 
the standard cut-off point for treatment outcome evaluation set by the ECDC is at 
twelve months, and distinguishing very early recurrences from treatment failures is 
challenging, especially in extrapulmonary cases and in pulmonary cases when sputum 
samples are not obtained during follow-up (Dale et al., 2017; Pettit et al., 2011). 
However, including very early recurrences would have increased the rate of recurrent 
TB at most by 10 cases to 0.7%. Furthermore, excluding cases who did not complete 
treatment in the former TB episode, which has been done in many other studies, 
would have decreased our amount of recurrent TB cases by almost one third 
(Parvaresh et al., 2018; Schiroli et al., 2015). 
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A more comparable way of evaluating the rate of recurrent TB is calculating the 
incidence of recurrent TB/100 000 patient years of follow-up and comparing it with 
the overall incidence of TB, but this has been published very rarely (Rosser et al., 
2018). Even though a complex way due to its need for information of individual 
follow-up times for each case in the cohort, this is necessary for cohorts with a high 
proportion of elderly patients that result in high mortality during follow-up. The 
overall incidence of TB recurrence in our study, 113/100 000 patient years, is the 
second lowest published so far (Dobler et al., 2009). We found that the first two 
years of follow-up have the highest risk for TB recurrence with incidences higher 
than 200/100 000 patient years of follow-up. As far as we know, this is the first study 
to publish the incidence of TB recurrence at different time points of follow-up. 
Persons with an earlier episode of TB should be recognised as a high-risk group for 
TB, because we found that TB incidence among them is 10-20 times higher than in 
the population during the study period. A very high-risk period for TB recurrence is 
the first two years after a TB episode.  
6.3 Distinguishing relapses from re-infections among recurrent 
TB cases and the use of whole genome sequencing 
Our observation of more than 80% of recurrent cases resulting from relapses is in 
line with other studies published from low-incidence countries using traditional 
genotyping methods (Dobler et al., 2009; Rosser et al., 2018). We used a novel 
genotyping method, whole genome sequencing, which has lately been shown to 
discriminate strains with a higher sensitivity (Nikolayevskyy et al., 2019). Our study 
was the first published from a low-incidence country using WGS in this setting. We 
showed that the number of mutations between isolates of subsequent TB episodes 
is not always as clearly polarised as was shown in two earlier studies from countries 
with high TB incidences (Bryant et al., 2013; Guerra-Assuncao et al., 2015). In our 
study, one case classified as relapse based on similar spoligotypes in both episodes 
was assessed as a re-infection based on WGS data. Recent studies have shown that 
distinguishing relapses from re-infections is not always possible, even when using 
WGS. Becoming re-infected with a similar or very closely related strain is probable 
in settings with a high predominance of genetically close strains (Folkvardsen et al., 
2020; Nikolayevskyy et al., 2019). However, a wide distribution of strains has been 
observed in Finland (Smit et al., 2013). 
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Whole genome sequencing is expected to replace variable earlier molecular and 
genotyping methods used for, e.g., identification of species and strains, detection of 
transmission chains and laboratory cross contaminations and for rapid identification 
of drug resistant isolates, and it can be established with accurate speed and with 
reasonable costs (Cabibbe et al., 2018; Nikolayevskyy et al., 2019; Pankhurst et al., 
2016). Some major limitations, such as the lack of international standardisation, the 
need for culture of M. tuberculosis isolates and advanced bioinformatics, have to be 
noticed (Pankhurst et al., 2016; Satta et al., 2018; van Soolingen et al., 2016). Very 
few studies with a very low number of M. tuberculosis isolates using whole genome 
sequencing to distinguish relapses from re-infections have been published so far. 
Our study found no relation between the number of mutations and the interval 
between TB episodes as well as the treatment outcome of the first episode among 
relapse cases. Other studies evaluating factors affecting the number of mutations 
among relapse cases have not been published to our knowledge, so further studies 
are needed to determine factors affecting the mutation rate.  
6.4 Risk factors for non-successful treatment 
Male gender is a risk factor for both death as outcome and for TB recurrence. Older 
age increases the risk for death, whereas younger age increases the risk for TB 
recurrence. The combined effect of comorbidities on the risk of death, using the 
Charlson comorbidity index, has been published very rarely earlier (Fløe et al., 2018).  
Drug resistance predicts non-successful treatment outcomes other than death. A 
pulmonary disease site strongly correlates with the risk of TB recurrence in the long 
run.  
6.4.1 Male gender 
Our observation of male gender as a risk factor for both death as outcome and for 
TB recurrence has been published in earlier studies, but the risk ratios between 
genders are exceptionally high in our study (Fløe et al., 2018; Kim et al., 2016). Other 
studies have also associated male gender with non-successful outcomes other than 
death (Holden et al., 2019; Stosic et al., 2020). We did not find this association, but 
the number of cases with other non-successful outcomes was low in our study.  
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We could not evaluate reasons for the risk differences between genders, because 
we did not have data on other risk factors, such as adherence to treatment, substance 
abuse and smoking, the severity of TB and the use of immunosuppressive 
medications, for the cases in the cohorts. An unexpected finding was that among 
recurrent TB cases, the treatment outcomes of the episodes preceding recurrence 
were successful among males more than twice as commonly as among females. This 
means that other risk factors may be more common among men. Poor treatment 
adherence and substance abuse may at least partly explain this. We found that among 
recurrent cases, almost two thirds of males and no females had a history of substance 
abuse, mostly alcohol. The risk of alcohol use disorders in the Finnish population is 
about four fold among men compared to women and decreases with increasing age 
above age group 30-44 years (Peña et al., 2018). Alcohol abuse has been associated 
with poor treatment adherence in recurrent TB (Selassie et al., 2005). Furthermore, 
other studies have shown an association between alcohol abuse and death with TB 
(Volkmann et al., 2016; Waitt et al., 2011). 
6.4.2 Age 
We found that older age increases the risk for death with TB, whereas younger age 
increases the risk for TB recurrence. Increasing age has been associated with the risk 
of death with TB in several studies, but our observation of a greater risk increase 
with age among females than males has not been published earlier, as far as we know 
(Stosic et al., 2020; Vasankari et al., 2007). This may reflect that differences in other 
risk factors between genders are more prevalent among younger age groups. Even 
though death as outcome was 10 times more common among Finnish-born than 
foreign-born cases, origin was not an independent risk factor for death due to 
strikingly differing age distributions between these two groups.  
We observed that younger age increases the risk for TB recurrence, whereas two 
earlier studies have shown that patients aged >65 years and between 25-44 years 
have a higher risk for TB recurrence (Kim et al., 2016; Selassie et al., 2005). We are 
unable to evaluate the reasons for this finding, but it may be explained by more 
prevalent risk factors among younger TB cases, as described earlier. 
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6.4.3 Comorbidities 
Comorbidities are common when the proportion of elderly patients is high. Several 
non-infective comorbidities, such as diabetes, COPD and severe kidney disease, 
have been associated with death as outcome among TB cases (Fielder et al., 2002; 
Oursler et al., 2002; Walpola et al., 2003). We assessed the combined effect of 
comorbidities on the risk of death, using the Charlson comorbidity index, and found 
that comorbidities were associated with death as outcome in all age groups. In 
addition, the higher the comorbidity index, the higher the risk for death. The only 
earlier study assessing the combined effect of comorbidities, using the Charlson 
comorbidity index, is from Denmark and shows that almost 90% of TB cases in their 
cohort had a Charlson index of zero at the time of TB diagnosis (Fløe et al., 2018). 
Less than half of the cases in our cohort have a Charlson index of zero, meaning 
that our TB patients have substantially more comorbidities. This, together with the 
high proportion of elderly patients in our cohort, at least partially explains the high 
proportion of death as outcome in our study.  
6.4.4 Drug resistance 
We found that drug resistance predicts non-successful treatment outcomes other 
than death. Among the group of non-defined treatment outcomes, this is explained 
by the justifiable extension of treatment for cases with drug resistance, resulting in 
categorisation in outcome group still on treatment at 12 months. 
Our observation of drug resistance as a risk factor for unsatisfactory outcomes 
as well as for solely outcomes failed and lost to follow-up combined is alarming, 
because cases with these outcomes may have potential to further transmit the 
disease. A recent multi-center European study described isoniazid resistance as a risk 
factor for non-successful treatment outcomes, also including cases with death as 
outcome, but this finding has been inconsistent (Bang et al., 2010; Cattamanchi et 
al., 2009; Karo et al., 2019). Our finding underscores the need for training for 
physicians and for updating national guidelines for treatment of drug resistant cases. 
Data on drug susceptibility were not available for all cases in the cohort until year 
2001, so we did not evaluate the impact of drug resistance on TB recurrence. Other 
studies have shown incompatible results concerning the risk of TB recurrence 
among cases with drug resistance, excluding MDR cases (Brugueras et al., 2020; 
Jasmer et al., 2004).  
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6.4.5 Pulmonary disease site  
We observed that the pulmonary disease site correlates with the risk for TB 
recurrence, which has also been shown in some earlier studies (Crofts et al., 2010; 
Kim et al., 2016). Over 40% of the recurrent cases in our study had coincidental 
pulmonary and extrapulmonary disease in the first episode (data not shown). Having 
both pulmonary and extrapulmonary infection has been associated with the risk of 
TB recurrence and outcome as death in earlier studies (Millet et al., 2009; Pradipta 
et al., 2018). Our study for treatment outcomes included only pulmonary TB cases, 
in line with most other studies; thus, we could not evaluate the risk differences for 
outcomes between pulmonary and extrapulmonary TB cases. A recent study from 
Serbia showed that death as outcome and outcome lost to follow-up are more 
common among pulmonary TB cases than extrapulmonary TB cases (Stosic et al., 
2020). However, in a Finnish cohort from the mid-1990s, pulmonary TB cases 
showed a higher treatment success rate due to lower proportions of outcomes lost 
to follow-up and still on treatment, even though death as outcome was more 
common among pulmonary cases (Vasankari et al., 2010; Vasankari et al., 2007). 
6.5 Validity of treatment outcomes notified and adequacy of 
prescribed treatment regimens in TB episodes preceding 
recurrence 
We evaluated the validity of treatment outcomes notified in the cohort of pulmonary 
TB cases and the adequacy of prescribed treatment regimens in TB episodes 
preceding recurrence and found substantial deviations from the guidelines. The 
actual treatments of the first episode among recurrent TB cases have rarely been 
published, and the adequacy of treatment regimens and the validity of notified 
treatment outcomes have not been assessed in earlier publications to our knowledge 
(Pascopella et al., 2011; Selassie et al., 2005).  
The median duration of TB treatment in our cohort of microbiologically 
confirmed pulmonary TB cases was almost 7 months. This is clearly longer than the 
standard treatment duration of 6 months recommended by WHO, which was the 
median duration of treatment in a recent study from Denmark (Holden et al., 2019). 
We used 5.5 months as minimum duration for adequate standard treatment in line 
with an earlier study from Finland (Vasankari et al., 2007). A high majority of studies 
on treatment outcomes do not present the duration of treatments, but in some 
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countries, such as in France, receiving at least 80% of the standard TB treatment, 
which means less than 5 months, is demanded for successful treatment outcomes 
(Guthmann et al., 2020). Less than 1% of cases with a successful outcome had 
received treatment for less than 5.5 months in our study, according to treatment 
durations notified. However, we found that almost 10% of cases with successful 
outcomes should have been classified with outcome still on treatment according to 
the national guidelines. The treatment outcome still on treatment is thus much more 
common than the 4% notified. In addition, almost one fifth of cases originally 
notified with an unsatisfactory treatment outcome were misclassified. Even though 
not published from other countries, shortcomings in treatment outcome evaluation 
are probably present globally considering the fact that in Finland, treatment outcome 
evaluation is recommended to be evaluated by one trained physician in each hospital 
district instead of the treating physician as in many countries. 
Almost one third of our recurrent cases had been prescribed with inadequate 
treatment in the TB episode preceding recurrence. In addition, almost 1 in 6 cases 
were still on treatment at twelve months. Suboptimal TB treatment has been 
associated with the risk of recurrence earlier, and treatment lasting for more than 12 
months has been associated with poor treatment adherence, a factor related to the 
risk of recurrence (Pascopella et al., 2014; Selassie et al., 2005). We could not evaluate 
the fulfillment of prescribed treatments, because this was a retrospective study, but 
DOT was implemented for only about 10% of cases in TB episodes preceding 
recurrence.  
A need exists to review national guidelines and provide further training for 
physicians treating TB cases and evaluating treatment outcomes due to shortcomings 
observed in allocation of treatment outcomes in the cohort and in prescribed 
treatment regimens in episodes preceding recurrence among recurrent cases. These 
shortcomings probably are widely present and should be taken into consideration 
when comparing the quality of TB treatment between countries, even though they 
are not published from other countries.  
6.6 Strengths and limitations 
The study’s strengths are the use of comprehensive national cohorts with large 
numbers of cases and the long study periods. The reporting rate for treatment 
outcomes was very high, 99%. We carried out careful validation for cases with 
suspected recurrent TB by assessing medical records data, which is rarely done in 
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register-based studies of recurrent TB. Furthermore, we used a novel, more 
discriminating genotyping method, whole genome sequencing, to distinguish 
relapses from re-infections. 
The main limitations of the study result from the retrospective, register-based 
cohort study design. We miss TB cases that are not notified to TTR, but the register 
has been shown to have high sensitivity and specificity for TB (Kokki et al, 2005). 
Only a limited amount of data is collected in TTR; therefore, we do not have cohort 
data on some factors that may have an effect on treatment success, such as substance 
abuse, the severity of the TB infection and the implementation of DOT. Some 
results are only descriptive, because we did not have a case-control study design. 
Additionally, only positive HIV test results are notified to TTR. 
Furthermore, our evaluation of the validity of notified treatment outcomes is not 
complete, because we did not have data on treatment regimens prescribed for cases 
notified with a successful outcome. Among recurrent cases, we could not evaluate 
adherence to treatment in the episodes preceding recurrence, because this was rarely 
mentioned in the medical records. The Charlson comorbidity index misses some 
disease groups which may have an impact on the treatment outcome, such as 
inflammatory bowel disease and vasculitis, in which immunosuppressive medication 
is commonly used.  
Finally, relapses were distinguished from re-infections among recurrent TB cases 
when isolates from both TB episodes were available for genotyping. The analysis 
could be performed for only half of the cases with at least two culture positive TB 
episodes. Until the year 2000, only every tenth M. tuberculosis isolate was stored frozen 
in the culture collection. The bias caused in the analysis is acceptable, because the 
decision to store frozen M. tuberculosis isolates in our national reference laboratory 
was random. 
6.7 Future considerations 
Treatment outcomes are notified for only pulmonary TB cases in Finland, so our 
study of treatment outcomes did not include extrapulmonary cases. A study with a 
medical records review is needed to evaluate treatment outcomes and current risk 
factors for non-successful outcomes among extrapulmonary TB cases. An additional 
study for MDR-cases, including evaluation of prescribed treatments and treatment 
outcomes, is in progress by our research group. 
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Only a few retrospective studies have classified cases with death as outcome as 
TB-related deaths and non-TB-related deaths (Beavers et al., 2018; Guthmann et al., 
2020). Even though complex, evaluating the importance of TB as a cause of death 
among fatal cases, preferably in a prospective study, would be particularly beneficial 
in Finland due to the high rate of death as outcome, as well as the high rate of 
confounding factors such as comorbidities and older age. Additionally, early deaths 
with TB are common, so the delays in TB diagnostics and reasons for the delays by 
the patient and the health care system should be evaluated to expedite and improve 
the diagnostics. A systematic review of delays in the diagnosis and treatment of 
tuberculosis found a wide variation in the length of the delays and the risk factors 
for diagnostic delays (Storla et al., 2008).  
Only a few studies, with low numbers of patients, distinguish relapses from re-
infections among recurrent cases (Rosser et al., 2018). The conclusions to be drawn 
for national TB control programs depend on the background of TB recurrence, 
because relapses and re-infections reflect clearly different situations. Differences in 
study designs, TB incidences and demographics also make interpreting published 
results difficult. Further prospective or case-control cohort studies for the risk 
factors of recurrent TB distinguishing relapses from re-infections are needed. 
Finally, the epidemiologic situation in Finland is changing gradually. TB among 
natives is decreasing with the decline of those generations, that were infected with 
TB decades ago. This, together with increasing immigration from countries with high 
TB incidences, is leading to a higher proportion of immigrants among TB cases 
(Räisänen et al., 2015). Consequently, TB cases are expected to be younger and have 
fewer comorbidities. The importance of other risk factors may rise, instead. It is 
therefore essential to continuously assess TB situation in Finland.  
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7 SUMMARY AND CONCLUSIONS 
Adequate TB treatment is important both to cure the patient and to decrease 
transmission together with early diagnoses and appropriate contact investigations. 
WHO recommends assigning treatment outcomes for all TB patients. Evaluation of 
treatment outcomes presents the efficacy of treatment in a shorter period. A more 
permanent cure can be assessed by evaluating TB recurrence. It is important to 
distinguish the two ways of recurrences, relapses and re-infections when evaluating 
the quality of TB treatment, because only relapses reflect shortcomings in the 
treatment of the previous TB episode.  
This study evaluated the quality of tuberculosis treatment in Finland by assessing 
treatment outcomes at one year and recurrence of tuberculosis in a longer period 
and determined some risk factors for non-successful treatment. 
 
The main findings and conclusions are as follows: 
 
1. The proportion of successful treatment outcomes is 75% among 
microbiologically confirmed pulmonary TB cases. The proportion of death 
as outcome is high (16%), whereas outcomes failed (0.2%), lost to follow-up 
(0.8%) and not known (2.5%), presenting cases that may have a potential to 
transmit the disease, are rare. 
2. Recurrent TB is rare in Finland (0.6% of the cases). However, persons with 
an earlier episode of TB constitute a high-risk group with 10-20 times higher 
incidence of TB than in the general population. 
3. A high majority (>80%) of recurrent cases are due to relapses. 
4. Male gender is a risk factor for both death as outcome and for TB recurrence. 
Older age increases the risk for death, whereas younger age increases the risk 
for TB recurrence. Comorbidities are common among TB cases and are 
associated with the risk of death in all age groups. Drug resistance predicts 
non-successful treatment outcomes other than death. A pulmonary disease 
site strongly correlates with the risk for TB recurrence in the long run. 
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5. There are substantial deviations from the guidelines in notified treatment 
outcomes and prescribed treatment regimens in TB episodes preceding 
recurrence.  
 
In conclusion, the rate of successful treatment outcomes is clearly below the 
target of 85% set by WHO. This is mainly due to the high proportion of death as 
outcome. The high mean age among Finnish-born cases and the presence of 
comorbidities at least partially explain this situation. However, because most fatal 
cases die early, better awareness of TB among the population and health-care 
professionals is needed to reach early suspicion and timely diagnosis and treatment 
of TB. Younger male patients show high relative risks for death as outcome as well 
as for TB recurrence, and cases with drug-resistant strains show high relative risks 
for non-successful outcomes other than death; thus, special attention should be paid 
to choosing the correct treatment regimens for them and to promoting treatment 
adherence using DOT. Finally, shortcomings observed in allocation of treatment 
outcomes in the cohort and in prescribed treatment regimens in episodes preceding 
recurrence show that a need exists to review national guidelines and to further train 
physicians treating TB cases.  
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Abstract
Background: Major transition in tuberculosis (TB) epidemiology is taking place in many European countries
including Finland. Monitoring treatment outcome of TB cases is important for identifying gaps in the national TB
control program, in order to strengthen the system. The aim of the study was to identify potential risk factors for
non-successful TB treatment outcomes, with a particular focus on the impact of comorbidities. We also evaluated
the treatment outcome monitoring system.
Methods: All notified microbiologically confirmed pulmonary TB cases in Finland in 2007–2014 were included,
except multi-drug resistant (MDR) cases. Nationwide register data were retrieved from: Infectious Diseases Register,
Population Register, Cause of Death Register and Hospital Discharge Register. Non-successful outcomes were
divided into three groups: death, unsatisfactory outcomes and non-defined outcomes. Logistic regression analyses
were used to identify risk factors for non-successful outcomes.
Results: Treatment outcomes were notified for 98.6% of study cases (n = 1396/1416). Treatment success rate was
75%. The main reason for non-successful outcome was death (16%), whereas outcomes failed and lost to follow-up
were rare (1% together). In a multivariable model, risk factors for death as outcome were increasing age, male
gender and Charlson comorbidity index ≥1, for unsatisfactory outcomes non-MDR drug resistance and TB
registered in the first study period, and for non-defined outcomes non-MDR drug resistance. Among 50 cases with
unsatisfactory outcomes, we observed false outcome allocations in eight (16%), and > 2% of the cases transferred to
another country or disappeared before or during treatment.
Conclusions: With a high proportion of older population among tuberculosis cases, death is a common treatment
outcome in Finland. Comorbidity is an important factor to be incorporated when interpreting and comparing
outcome rates. There was a considerable inconsistency in outcome allocation in the monitoring system, which
implies that there is need to review the guidelines and provide further training for outcome assessment.
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Background
Adequate TB treatment is important both for the recov-
ery of the patient and prevention of transmission, to-
gether with early diagnoses and appropriate contact
investigations. Tuberculosis treatment outcome moni-
toring is essential for evaluating the function of a na-
tional tuberculosis control program. European Centre
for Disease Prevention and Control (ECDC) [1] and
World Health Organization (WHO) [2] recommend
assessing outcomes for all TB cases with different cri-
teria and timing for drug-susceptible and multidrug-
resistant (MDR) TB. Recommendations by ECDC for
European Union/European Economic Area (EU/EEA)
countries are consistent with WHO recommendations,
except that the outcomes are assessed at the latest at 12
months after treatment initiation and hence an outcome
group of ‘still on treatment’ is included [1].
Treatment success rates in most European countries
do not reach the global target of 85% set by WHO, vary-
ing widely from 56% in Hungary to 89% in Norway dur-
ing 2002–2011 [3]. In 2015, WHO has set more
ambitious targets for treatment outcome, including suc-
cess of at least 90% by year 2025, as well as reducing tu-
berculosis deaths by 75% [4]. In routine outcome
monitoring from European region countries for cases
registered in 2016, treatment success rate was 75% and
proportion of fatal cases was 8% [1].
In Finland, with a current TB incidence rate of 4.1/
100000, the incidence among Finnish-born has de-
creased and immigration from high-TB-incidence coun-
tries has increased raising the proportion of TB cases
with foreign origins from 4% in 1995–1996 [5] to 40% in
2017 [6]. The majority of TB among the Finnish-born
population is in the elderly persons from reactivation of
a latent TB infection, reflected by the mean age of 71
years among Finnish-born TB cases in 2017, the highest
in the EU/EEA countries [1]. In countries with a high
proportion of elderly cases, comorbidities are common,
probably contributing to higher mortality observed in
TB outcome monitoring [7] and complicating the inter-
pretation of treatment non-success rates between
countries.
A previous cohort study of culture-confirmed pulmon-
ary TB cases registered in 1995–1996 in Finland showed
that there was a wide variety of TB treatment combina-
tions and durations [5]. Treatment success rate was 65,
and 19% of cases died before or during TB treatment
[5]. Thereafter, a National TB Control Program has been
published, with recommendations for TB treatment and
the use of directly observed treatment (DOT) for risk
groups in 2006 [8] and for all patients in 2013 [9].
The aim of our study was to identify potential risk fac-
tors for non-successful TB treatment outcomes, with a
particular focus on the impact of comorbidities. We also
evaluated the treatment outcome monitoring system in
order to identify ways to improve the treatment success
rate, and to strengthen the TB monitoring program in
the changing epidemiologic environment.
Methods
Data sources
Our cohort study was based on the data of National In-
fectious Diseases Register (NIDR), National Population
Register, Cause of Death Register and Finnish Hospital
Discharge Register. This study included all microbio-
logically confirmed pulmonary TB cases, except MDR-
TB cases, notified from January 1, 2007, to December
31, 2014, to the National Infectious Disease Register
(NIDR) (Fig. 1).
Reporting of TB cases to NIDR is mandatory to all
physicians and laboratories, and laboratories send an au-
tomated reminder to the treating physician of the obliga-
tion to notify, when TB is microbiologically confirmed.
The date of death is retrieved from the national popula-
tion registry and HIV cases are linked to TB cases in
NIDR. Data from the different sources are automatically
linked as a case by the unique national identifier. Follow-
ing data was collected from NIDR: patient identification
(name and unique national identifier), age, gender, origin
(country of birth or if unknown, nationality), place of
residence, a history of earlier TB diagnosis (since 1950)
and its treatment (year, did the patient receive (full)
treatment), ICD10 codes (International Classification of
Diseases, 10th Revision), microbiological test results in-
cluding the results of drug susceptibility testing in the
national reference laboratory, date of registration in
NIDR, and the intent to give full TB treatment.
Since 2007, treatment outcomes for all microbiologic-
ally confirmed pulmonary TB cases in Finland are noti-
fied to NIDR according to the WHO/IUATLD
recommendation for EU/EEA countries [10] with two
additional categories ‘Still on treatment’ [1] and ‘Notified
not known’ (Fig. 2). At 12 months from the date of regis-
tration, NIDR sends a request for outcome notification
to the hospital district (n = 20), from which the TB case
was originally notified. Outcome notification includes
data on treatment of the current TB episode (dates on
treatment commencement and cessation, total duration
of treatment interruptions, duration of rifampicin plus
isoniazid given concomitantly), the patient moving to
another hospital district during treatment and the dis-
trict to which the case moves. One trained physician no-
tifies all outcomes in each hospital district. For cases
with outcomes failed, lost to follow-up and notified as
not known, we acquired additional information from the
notifying health care facility to assess whether the out-
comes had been notified correctly.
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Fig. 1 Steps in identifying cases for treatment outcome evaluation, Finland 2007–2014
Fig. 2 Treatment outcomes in 1416 microbiologically confirmed pulmonary non-MDR TB cases, 2007–2014
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For cases with death as outcome, we obtained the struc-
tured data on the causes of death from the Cause of Death
Register at Statistics Finland, in order to determine whether
death was TB-related. A death was classified as TB-
associated, if TB was the immediate or underlying cause of
death or a significant condition contributing to death.
To assess comorbidities, all diagnoses, coded in
ICD-10 for study cases, were obtained from National
Hospital Discharge Register [11] three years preceding
and one year following TB registration date. Comor-
bidity scores were calculated using the model devel-
oped by Charlson et al. [12]. The Charlson-Deyo [13]
comorbidity index contains 17 diagnostic groups for
chronic diseases with a weighted score that is associated
with 1-year mortality, and the model has been used with
administrative register data, and with ICD-10 diagnostic
codes [14].
Analysis and statistics
According to the WHO criteria [2], successful treatment
outcome includes cases with completed treatment, with
or without microbiological evidence of cure. For statistical
analysis, we combined failed cases, with a positive culture
or sputum smear at 5months or later, cases with out-
comes lost to follow-up (treatment interrupted) and noti-
fied not known, including transferred out cases, as a
group of unsatisfactory outcome (Fig. 2). Cases with out-
comes still on treatment and not notified were combined
as a group of non-defined outcome. Death as outcome in-
cludes also cases diagnosed post mortem (e.g. at autopsy).
The allocation of each case in outcome grouping in Fig.
2 is based on the original routine outcome notification. For
the study, patient chart review was performed for cases
with outcomes failed, lost to follow-up and notified not
known. We used 5.5months as the minimum duration for
full treatment, as described in our previous study [5]. We
used logistic regression analyses for modelling the outcome
of tuberculosis treatment. Apart from well-known risk fac-
tors, we incorporated in the multivariable analysis the vari-
ables with a 20% likelihood in the univariate analysis, as
well as the Charlson comorbidity score. We used multi-
imputation of the missing data of some variables with the
MICE algorithm [15] assuming that the missing values
were randomly distributed (MAR). In the model, the shape
of the variable age was selected using Akaike information
criteria (AIC) [16] because of the high risk of death among
the very young children (J-shaped curve). We found that
the inverse of age (1/age) was a parsimonious way of mod-
elling the young age effect on the mortality. Furthermore,
we incorporated into the model the variables with interac-
tions with age, for which statistical evidence was seen with
e.g. AIC. Due to possible clustering in hospital district
level, robust standard error estimators were used in the
model.
Results
Of the 1785 pulmonary TB cases notified during 2007–
2014, we identified 1416 bacteriologically confirmed
non-MDR cases (Fig. 1). The proportion of males was
64.6% and those of foreign origin 27.3%. Three most fre-
quent countries of birth among foreign-born cases were
Somalia, Vietnam and countries of the former Soviet
Union. The median age of cases was 60 years (range, 0–
98 years). Finnish-born cases were significantly older
(median age 70 vs. 28 years, p < 0.001) and had more co-
morbidities (Charlson comorbidity index> 0 in 61.9% vs.
22.1%, p < 0.001) than cases with foreign origins. Of the
M. tuberculosis isolates, 89.1% were fully susceptible.
The proportions of mono-resistant and non-MDR poly-
resistant isolates were 6.5 and 1.8%, respectively.
Twenty-five cases (1.8%) were HIV positive.
Treatment outcomes and treatment duration
Treatment outcome was notified for 1396 cases (98.6%)
(Fig. 2). Successful treatment outcome was achieved in
1063 cases (75.1%). When calculated for only cases with
a notified outcome, treatment success rate was 76.1%.
The main reason for non-successful outcome was death
in 231 cases (16.3%). Outcomes ‘failed’ and ‘lost to
follow-up’ together accounted for 15 cases (1.0%).
Among the 1204 cases with data on treatment dur-
ation, median duration was 204 days (interquartile range
(IQR), 183–278 days). Among cases notified as success-
fully treated and with data on treatment duration (n =
1010/1063), 6 cases (0.6%) received treatment for less
than 5.5 months, 913 cases (90.4%) for 5.5 months to
one year, and 91 cases (9.0%) for more than a year.
Among cases with outcome lost to follow-up (treatment
interrupted) and with data on treatment duration (n =
10/12), one (10%) did not receive any medication, five
(50%) received treatment for less than 5.5 months, three
(30.0%) for 5.5 months to one year and one (10%) for
more than one year. Data on the duration of pauses in
treatment was available for 773 (64.2%) of the 1204
cases. Among these, TB treatment was discontinued for
at least one day for 242 cases (31.3%) and the mean dur-
ation of the sum of pauses was 6.7 days per patient.
Fatal cases
The proportions of death as outcome for Finnish-born
and foreign-born cases were 21.8 and 1.6%, respectively.
The median time from the date of registration to death
was 44 days (IQR, 12–121 days). Among the 150 cases
who received TB medication, with data on treatment
duration, 81 cases (54.0%) received medication for less
than 2 months, 56 (37.3%) for two to less than 5.5
months, 12 (8.0%) for 5.5 months to a year and one
(0.7%) for more than a year. Fifty-eight (25.1%) fatal
cases did not receive any TB medication.
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According to death certificates, death was classified as
TB-associated in 167 fatal cases (72.3%); in 101 (43.7%)
TB was as the immediate or underlying cause of death,
and in 64 (28.6%) as a significant condition contributing
to death. Charlson comorbidity scores for cases with
TB-associated death did not differ from scores for non-
TB-associated deaths (p = 0.13).
In univariate analysis, risk factors for death were in-
creasing age, male gender, Finnish origin and Charlson
comorbidity index ≥1 (Table 1). In multivariate logistic
regression model, independent association for death as
outcome was observed with increasing age, male gender
and Charlson comorbidity index (Table 2). Interaction
was observed between age and gender. The association
Table 1 Univariate analysis for risk factors for non-successful outcomes in 1416 pulmonary non-MDR TB cases
Variable Category Successful
(n = 1063)
Died
(n = 231)
Univariate RRRa
for deathb
(95%CI)
p
Unsatisfactoryc
(n = 50)
Univariate RRRa
for unsatisfactoryb
(95%CI)
p
Non-
defined
(n = 72)
Univariate RRRa
for non-definedb
(95%CI)
p
Age Age/10 years Median 57
years
Median
79 years
1.77
(1.53–2.06)
< 0.001
Median 27.5
years
0.65
(0.59–0.72)
< 0.001
Median
51.5 years
0.96
(0.87–1.05)
0.341
Gender Female (n =
501)
n = 387
(77.2%)
n = 68
(13.6%)
1 n = 17
(3.4%)
1 n = 29
(5.8%)
1
Male (n =
915)
n = 676
(73.9%)
n = 163
(17.8%)
1.37
(1.06–1.77)
0.015
n = 33
(3.6%)
1.11
(0.68–1.82)
0.677
n = 43
(4.7%)
0.85
(0.49–1.46)
0.552
Origin Finnish (n =
1030)
n = 744
(72.2%)
n = 225
(21.8%)
1 n = 13
(1.3%)
1 n = 48
(4.7%)
1
Foreign (n =
386)
n = 319
(82.6%)
n = 6
(1.6%)
0.06
(0.04–0.11)
< 0.001
n = 37
(9.6%)
6.64
(3.68–11.98)
< 0.001
n = 24
(6.2%)
1.17
(0.70–1.93)
0.551
Drug resistance
non-MDRd
No (n =
1262)
n = 966
(76.5%)
n = 207
(16.4%)
1 n = 38
(3.0%)
1 n = 51
(4.0%)
1
Yes (n = 118) n = 74
(62.7%)
n = 12
(10.2%)
0.76
(0.33–1.74)
0.511
n = 12
(10.2%)
4.12
(2.02–8.41)
< 0.001
n = 20
(16.9%)
5.12
(3.23–8.11)
< 0.001
Sputum smeare Negative
(n = 629)
n = 481
(76.5%)
n = 96
(15.3%)
1 n = 23
(3.7%)
1 n = 29
(4.6%)
1
Positive (n =
694)
n = 527
(75.9%)
n = 105
(15.1%)
0.998
(0.82–1.21)
0.986
n = 24
(3.5%)
0.95
(0.48–1.87)
0.888
n = 38
(5.5%)
1.20
(0.80–1.79)
0.387
Study period 2007–2010
(n = 760)
n = 570
(75.0%)
n = 118
(15.5%)
1 n = 31
(4.1%)
1 n = 41
(5.4%)
1
2011–2014
(n = 656)
n = 493
(75.2%)
n = 113
(17.2%)
1.11
(0.88–1.39)
0.383
n = 19
(2.9%)
0.71
(0.51–0.99)
0.045
n = 31
(4.7%)
0.87
(0.43–1.77)
0.709
Charlsonf 0 (n = 631) n = 550
(87.2%)
n = 30
(4.8%)
1 n = 17
(2.7%)
1 n = 34
(5.4%)
1
1–2 (n =
462)
n = 322
(69.7%)
n = 111
(24.0%)
6.32
(4.57–8.74)
< 0.001
n = 9
(2.0%)
0.90
(0.30–3.73)
0.859
n = 20
(4.3%)
1.00
(0.60–1.67)
0.985
3–4 (n =
172)
n = 109
(63.4%)
n = 54
(31.4%)
9.08
(5.63–14.66)
< 0.001
n = 1 (0.6%) 0.30
(0.04–2.36)
0.251
n = 8
(4.7%)
1.19
(0.50–2.82)
0.697
≥5 (n = 85) n = 52
(61.2%)
n = 28
(32.9%)
9.87
(4.63–21.06)
< 0.001
n = 1 (1.2%) 0.62
(0.11–3.67)
0.600
n = 4
(4.7%)
1.24
(0.55–2.79)
0.596
aratio of relative risks
bcompared to successfully treated cases
c including cases transferred out
dInformation missing for 36 cases (23 successfully treated cases, 12 fatal cases, 1 non-defined case)
eInformation missing for 93 cases (55 successfully treated cases, 30 fatal cases, 3 other defined unsuccessfully treated cases, 5 non-defined outcome)
fInformation missing for 66 cases (30 successfully treated cases, 8 fatal cases, 22 other defined unsuccessfully treated cases, 6 non-defined outcome)
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of higher Charlson index with increased risk for death
was seen in all age groups (data not shown).
Unsatisfactory outcomes
Among the 12 cases with outcome lost to follow-up,
premature treatment cessation was due to an adverse re-
action in three cases, non-compliance because of sub-
stance abuse in four, and in one, a positive TB culture
had been missed. Among the 35 cases notified as out-
come not known, 33 cases were of foreign origin. Out of
the 35, 25 transferred to another country before or dur-
ing TB treatment, three transferred within Finland and
four cases disappeared. Among the 50 cases with unsat-
isfactory outcomes, we observed false outcome alloca-
tions in eight cases (16%).
In univariate analysis, risk factors for unsatisfactory
outcome (failed, lost to follow-up and notified not
known) were younger age, foreign origin, non-MDR
drug resistance and TB registered in the first study
period (years 2007–2010) (Table 1). In multivariable lo-
gistic regression model, an independent association was
observed with non-MDR drug resistance (ratio of rela-
tive risks (RRR), 2.6; 95% confidence interval (CI), 1.2–
5.8) and TB registered during the first study period
(RRR, 1.5; 95%CI, 1.1–2.1). Interaction was observed be-
tween age and origin. When we restricted analysis to
only outcomes ‘failed’ and ‘lost to follow-up’ combined,
we found that non-MDR drug resistance was a clear pre-
dictor for these outcomes (univariate RRR, 4.75; 95%CI,
2.05–11.02, multivariate RRR, 4.93; 95%CI, 2.26–10.74).
Non-defined outcomes
Among the 52 cases with outcome still on treatment at
12 months, the reasons for extension of treatment was
reported for 36 cases (69%) and were following: having
non-MDR drug resistant isolate (n = 19), miliary/dissem-
inated disease (n = 5), advanced cavitary disease (n = 4),
pauses on treatment because of adverse drug reactions
(n = 4), bone and joint tuberculosis (n = 2), recurrent TB
(n = 1) and prolonged sputum culture positivity (n = 1).
Only non-MDR drug resistance was associated with
non-defined outcome in univariate (Table 1) and multi-
variable regression analysis (RRR, 5.6; 95%CI, 3.8–8.1).
Quality of treatment outcome allocations and treatment
follow-up
Based on the patient chart review and additional infor-
mation in the notifications of the 50 cases with an unsat-
isfactory outcome, we observed false outcome
allocations in eight cases (16%): four among cases with
outcome lost to follow-up, three among cases with out-
come not known and one among cases with outcome
failed. Among these eight, two should have been catego-
rized as successful outcome, two still on treatment, one
not known (transferred) and three lost to follow-up, in-
cluding one refusal. According to the additional data
mentioned above, 26 (1.8% of all) cases transferred to
another country and seven (0.5%) cases disappeared be-
fore or during TB treatment. Among the 31 cases who
were originally notified as not known (transferred to an-
other hospital district in Finland during TB treatment),
the final treatment outcome was notified for 28 (90.3%)
(2 still on treatment, 1 died, 25 successful). Among cases
notified as successfully treated and with data on treat-
ment duration (1010/1063, 95%), 91 cases (9.0%) had re-
ceived treatment for more than a year according to the
outcome notification.
Discussion
Our population-based cohort study on risk factors for
non-successful treatment outcomes of 1416 pulmonary
TB cases during 2007–2014 in Finland indicates that co-
morbidities, in addition to age and male gender, have an
independent contribution to death as outcome. Death
constituted two thirds of the non-successful outcomes
and was the main reason for the proportion of successful
outcomes remaining far below the 85% success rate ob-
jective set by the WHO.
Although there has been a minor decline in death as
outcome in pulmonary TB in Finland from 19% in
1995–1996 [5] to current 16%, the proportion of death
as outcome is still remarkably higher than the overall 7
% found in the 16 EU/EEA countries in 2002–2011 [3].
However, this is in line with some other European coun-
tries, e.g. Czech Republic (18%) and Slovenia (14%), with
Table 2 Multivariable analysis for risk factors for death in 1416
pulmonary non-MDR TB cases
Variable Multivariable RRRa
for death (95% CI)
p
Age/10 yearsb
Finnish male 1.50 (1.25–1.80) < 0.001
Finnish female 1.94 (1.42–2.65) < 0.001
Foreign origin male 1.20 (0.92–1.57) 0.183
Foreign origin female 1.55 (1.04–2.30) 0.030
Male 9.54 (1.36–66.70) 0.023
Foreign origin 1.01 (0.20–5.21) 0.991
Drug resistance non-MDRc 0.84 (0.33–2.11) 0.705
Study period 2011–2014 1.06 (0.80–1.40) 0.695
Charlson 1–2d 3.03 (2.11–4.35) < 0.001
Charlson 3–4d 3.55 (2.20–5.75) < 0.001
Charlson ≥ 5d 5.94 (2.65–13.33) < 0.001
aratio of relative risks
b1/age was also included in the model to explain the increase in the
risk of death among very young children (curve J-shaped), p < 0.001.
cInformation imputed for 23 successfully treated cases, 12 fatal cases
dInformation imputed for 30 successfully treated cases, 8 fatal cases
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similar demographics among TB patients [17, 18]. Earl-
ier studies have shown several non-infective comorbidi-
ties, e.g. diabetes [19, 20], liver [21] and kidney disease
[19–21] as well as COPD [19], to be associated with
death as outcome, but the combined effect of comorbidi-
ties on death with TB has rarely been studied [7]. In a
case-control register study from Denmark [7], comorbid-
ities were shown to be associated with death, and mor-
tality among TB cases was significantly higher than
among matched controls for all age groups above twenty
years. With a median age as high as 70 years among
Finnish-born patients, comorbidities are common. Using
the Charlson comorbidity index [12, 14] we found an as-
sociation between comorbidity and the risk of death; this
was seen in all age groups. Beside the fact that comor-
bidities may directly cause death in a patient with TB,
they also may cause delays in TB diagnostics by offering
alternative explanations for patients’ symptoms. In a
study from the US, tuberculosis-related deaths were as-
sociated with patients having an alternative diagnosis,
e.g. pneumonia, before TB diagnosis [22]. In our study,
two thirds of fatal cases with data on TB treatment dur-
ation died before treatment was started or received
treatment for less than two months (early deaths with
TB). This is in line with previous studies from California
[23] and North Carolina [24], emphasizing that TB diag-
nosis is often missed or delayed with current diagnostic
tools. We did not find a clear difference in Charlson co-
morbidity scores between cases with TB-associated and
non-TB-associated death according to data on death cer-
tificates. It has been stated that the diagnostic accuracy
of death certificate data is often poor [25, 26], especially
when death takes place outside hospital [27].
We found a striking difference between Finnish-born
cases and those with foreign origins: over one-fifth of
Finnish-born cases versus less than 2 % of those with
foreign origins had death as outcome, but origin was not
independently associated with death in multivariable
analysis. Male gender was a risk factor for death as out-
come, consistent with our earlier study in Finland [28]
as well as previous reports from other low-incidence
countries [3, 7, 29]. We were not able to evaluate rea-
sons for the large risk difference between genders par-
ticularly at young age groups, because we did not have
data on several risk factors, such as alcohol and sub-
stance abuse, the use of immunosuppressive medications
and the implementation of directly observed therapy
(DOT). Alcohol abuse has been associated with death
among TB cases in several studies [23, 24, 30] and espe-
cially among patients younger than 65 years [31].
Outcomes ‘failed’ and ‘lost to follow-up’ combined
accounted for only 1% of outcomes in our study, which
is far less than the 8% found in the 16 EU/EEA countries
in 2002–2011 [3]. We observed that non-MDR drug
resistance was a risk factor for outcomes ‘failed’ and ‘lost
to follow-up’ combined, as well as for the group of un-
satisfactory outcomes, which includes also cases with
outcome notified as not known. Isoniazid resistance has
been described as a risk factor for non-successful treat-
ment, including also fatal cases, in earlier studies in low-
incidence countries [32, 33], but this finding has been
inconsistent [34, 35]. Our finding underscores the need
for training physicians and having a special focus in the
national guidelines on appropriate treatment of drug re-
sistant cases and the importance of routine pheno- and
genotypic drug-susceptibility testing. Even though our
study period did not include the year 2015, when large
numbers of asylum seekers arrived Finland, more than
2% of cases transferred to another country or disap-
peared before or during TB treatment. This results at a
high risk of treatment interruption, and the potential for
continued transmission, and stresses the need to develop
a system to inform the known or probable receiving
country when a TB patient emigrates or disappears.
When evaluating the quality of treatment outcome no-
tifications, we observed that 16% of cases originally noti-
fied with an unsatisfactory outcome had been
misclassified. Furthermore, almost 10% of cases notified
as successfully treated, whose treatment duration was re-
ported in the outcome notification, should have been
categorized as still on treatment according to the na-
tional guidelines, which sets the evaluation at 12 months
from case registration. This suggests that outcome as-
sessment has a considerable rate of deviations from
guidelines, even when it is performed by one trained
specialist in each hospital district. This, together with
our observations on the effect of comorbidity, should be
taken into consideration when comparing countries and
developing European statistics on TB.
The strengths of this nationally comprehensive cohort
study include the observed high reporting rate at almost
99% for pulmonary tuberculosis in the mandatory TB
outcome reporting. NIDR sends a request for outcome
notification to the hospital district at 12 months from
the date of registration, and actively follows up for miss-
ing notifications. In addition, the outcome surveillance
system was efficient in monitoring transfer of cases
within Finland during treatment. We have previously
shown a high coverage for the TB surveillance system
[36], after which integration of automated mechanisms
for laboratory notifications and automated laboratory re-
minder of obligation to notify TB to the treating phys-
ician have been added, ensuring a high coverage and
representativeness of the data used. Comorbidities were
retrieved from National Hospital Discharge Register,
which has a high sensitivity and specificity for the com-
mon disease groups [11] constituting a major part of the
Charlson comorbidity index.
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Limitations of our study include the fact that we did
not have data on some known risk factors, particularly
substance abuse. Furthermore, we did not have data on
concomitant severe extrapulmonary TB manifestations,
such as meningeal TB. Until 2013, DOT was recom-
mended in national guidelines [8] for only certain risk
groups, e.g. alcohol or substance abuse, elderly patients
and patients with many comorbidities, but the absence
of data on DOT use is unlikely to introduce a major bias
on our analysis. Additionally, Charlson comorbidity
index does not contain all disease groups, which may in-
fluence TB treatment outcome, such as inflammatory
bowel disease and vasculitis, in which immunosuppres-
sive medication is commonly used. Less than 2% of TB
cases were HIV positive, and as a country with a very
low incidence for HIV [6], the absence of HIV test re-
sults is unlikely to introduce a bias. Treatment outcomes
for solely clinically diagnosed TB cases have been noti-
fied only since year 2015 in Finland.
Conclusions
With a high proportion of older population among TB
cases, death is a common treatment outcome in Finland.
Comorbidities contribute to death with TB in all age
groups, and two thirds of deaths occur within two
months after TB registration. Increased awareness of TB
as well as a low threshold for TB suspicion and diagnos-
tics is needed. In addition, early empiric TB treatment
when the suspicion of TB is strong and sufficient mater-
ial for TB diagnostics have been collected, as well as ad-
equate treatment of comorbidities during TB treatment
should be emphasized. Moreover, a special focus should
be given in the national guidelines on the treatment of
non-MDR drug resistant cases, as these are at risk for
other non-successful outcomes than death. Furthermore,
as we identified errors in outcome allocation, there is a
need to review guidelines and provide further training in
outcome assessment.
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Abstract
Background: We investigated the epidemiology and prevalence of potential risk factors of tuberculosis (TB)
recurrence in a population-based registry cohort of 8084 TB cases between 1995 and 2013.
Methods: An episode of recurrent TB was defined as a case re-registered in the National Infectious Disease Register
at least 360 days from the date of the initial registration. A regression model was used to estimate risk factors for
recurrence in the national cohort. To describe the presence of known risk factors for recurrence, patient records of
the recurrent cases were reviewed for TB diagnosis confirmation, potential factors affecting the risk of recurrence,
the treatment regimens given and the outcomes of the TB episodes preceding the recurrence.
Results: TB registry data included 84 patients, for whom more than 1 TB episode had been registered. After a careful
clinical review, 50 recurrent TB cases (0.6%) were identified. The overall incidence of recurrence was 113 cases per
100,000 person-years over a median follow up of 6.1 years. For the first 2 years, the incidence of recurrence was over
200/100000. In multivariate analysis of the national cohort, younger age remained an independent risk factor at all time
points, and male gender and pulmonary TB at 18 years of follow-up. Among the 50 recurrent cases, 35 patients (70%)
had received adequate treatment for the first episode; in 12 cases (24%) the treating physician and in two cases (4%)
the patient had discontinued treatment prematurely. In one case (2%) the treatment outcome could not be assessed.
Conclusions: In Finland, the rate of recurrent TB was low despite no systematic directly observed therapy. The first 2
years after a TB episode had the highest risk for recurrence. Among the recurrent cases, the observed premature
discontinuation of treatment in the first episode in nearly one fourth of the recurrent cases calls for improved training
of the physicians.
Keywords: Tuberculosis recurrence, Tuberculosis epidemiology, Tuberculosis treatment, Tuberculosis
Background
Tuberculosis (TB) remains a major global health
problem with estimated 10.4 million new TB cases
worldwide in 2015. In 2013, 0.3 million TB cases
were reported as recurrent [1]. After successful treat-
ment, recurrent TB is estimated to occur in 0–14% of
all TB patients within 1–3 years [2]. Recurrence of
TB following treatment of an initial disease episode
can occur due to endogenous re-activation with the
same strain of Mycobacterium tuberculosis (relapse) or
exogenous infection with a new strain (re-infection).
In low-incidence countries, recurrence rates have
varied between 0.4% and in a prospective clinical trial
up to 6% [3–5]. The proportion due to re-infection
has been reported to vary between 4 and 27% [3, 4].
In high-incidence countries the majority of recurrent
cases, up to 77%, are caused by re-infection [6].
Finland is a low-TB-incidence (<10/100000) country
since 2001, and in 2015 TB incidence was 5/100000 [7].
In 2015, 1% of TB cases had HIV infection. However,
emerging challenges for the TB control program include
gradually increasing resistance of M. tuberculosis, with
3% of all isolates multi drug resistant (MDR) in 2015 [7],
concomitantly with a rapid increase in the proportion of
TB cases occurring in immigrants [8]. Finland did not
implement a comprehensive DOT (directly observed
therapy) strategy in patient management until 2013 [9].
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Our previous study shows, that in Finland more than
80% of recurrent cases during 1995–2013 were relapses
[10]. The aim of the present study was to investigate in a
national, population-based TB cohort the occurrence of
recurrent TB and a few potential factors affecting the risk
of recurrence in Finland during the years 1995–2013. In
recurrent cases, we describe treatment regimens adminis-
tered and treatment outcome in the first episode, and
other potential factors affecting the risk of recurrence, in
order to strengthen the TB treatment program in the
changing epidemiologic environment.
Methods
Surveillance system and study population
The study population consisted of all TB cases in Finland
reported from January 1, 1995, to December 31, 2013, to
the National Infectious Disease Register (NIDR), main-
tained at the National Institute for Health and Welfare
(THL). Clinical microbiology laboratories mandatorily
notify new M. tuberculosis isolations to NIDR and submit
isolates to the Mycobacterial Reference Laboratory (NRL)
at THL for drug susceptibility testing (ethambutol,
isoniazid, pyrazinamide, rifampicin and streptomycin).
Physicians mandatorily notify to NIDR laboratory-
confirmed cases of TB: the laboratory report of a positive
test result to the clinician automatically includes a
reminder to notify the case. Since 2007, also clinically
diagnosed TB cases, when a decision to give a full course
of TB treatment is made, are notified. Information on HIV
positivity is obtained by linking data within NIDR. Data
on the country of origin and the date of death were
retrieved from the national population registry. Data from
the different sources are automatically linked as a case by
a unique person identifying number.
Case definitions and data collection for the subgroup of
recurrent cases
An episode of recurrent TB was defined as a case re-
registered in NIDR at least 360 days from the date of the
initial registration of a TB infection episode. For the cases
who had a recurrent episode in the register, data on
anatomical site of disease (pulmonary/extrapulmonary),
radiological, histological and microbiological results, HIV
test results, substance abuse, the drug regimen in the first
episode and adverse effects were extracted from patient
charts. In pulmonary TB cases, also sputum smear and
culture results at months 0 and 2, and at the end of the
treatment were obtained. Based on careful review of these
data, a number of cases were excluded from further
analysis as recurrent cases, as they did not meet the
criteria for recurrent TB (Fig. 1). In culture negative
episodes, the diagnoses were based on clinical criteria
[11], including radiological findings in combination with
either histological confirmation or positive nucleic acid
amplification test results, except for one case in which the
diagnosis was only clinical and radiological.
Management of the TB episode preceding recurrence
The treatment regimen, free of charge for the patient,
administered in the first TB episode was grouped into
six categories, based on the national recommendations:
until 2006 as described earlier [12, 13], and from 2006 in
the National TB Control Program [9]. The treatment
regimens and the outcomes of the first TB episodes of
the recurrent cases, including culture negative and extra-
pulmonary cases, were assessed by two clinical TB
experts, and classified [11] as cured, completed treat-
ment, lost to follow-up and not evaluated (no fatal cases
nor failures). ‘Lost to follow-up’ was further divided into
subgroups: physician’s decision to stop prematurely
(including cases that received ineffective treatment), and
defaulted (interruption due to the patient). Group ‘not
evaluated’ was further divided into subgroups: still on
treatment at 12 months, and treatment outcome not
assessed. In two cases the details of treatment in the first
episode were not available, but in one of these cases the
treatment outcome could be assessed.
Statistical analysis
To calculate the incidence of recurrent TB among all
reported cases of the national cohort, follow-up time in
days was calculated for all cases in the national TB
cohort from 360 days after they were notified until an
event (re-notification), death or censored (December 31,
2013). The date of death was acquired by linkage to
population register using person identifier. The regres-
sion model employed, uses pseudo-observations to
model censored data [14] with Stata version 14.02
(StataCorp LLC, 4905 Lakeway Drive, Collage Station,
TX 77845 USA) to estimate effects (their relative risks)
of risk factors. The censoring was assumed to be inde-
pendent, conditional on the covariates [15]. Gender and
anatomical site of disease were allowed to have time
dependent effects, and predictive margins were calcu-
lated to estimate cumulative risk differences between
genders and anatomical sites of disease, respectively,
adjusting for other factors in the model. Results were
qualitatively checked using the extended time dependent
Cox model. All the explanatory variables with univariate
p-values <0.2 were included in the multivariate model,
and included gender, anatomical site of disease and age.
Cause specific cumulative risks for time points 1 year,
2 years and 18 years were calculated, as the chosen early
time points had most recurrent events for explanatory
variables, and it has been previously reported that the
first 1–2 years have the highest hazard for recurrence
[3, 16]. The maximum surveillance time point set at
18 years gives the final overall difference estimate for
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the cumulative risk of recurrence. The distribution of
continuous variables between groups was compared
using Wilcoxon rank-sum test.
Ethics
The ethics approval for the study was given by the
Ethics Committee of Tampere University Hospital,
Tampere, Finland.
Results
A total of 8084 TB cases were registered in Finland during
the study period (Table 1): 43% were female, and 13.6% of
foreign origin (increased from 4.8% in 1995 to 32.2% in
2013). The median age was 70 years (interquartile range
[IQR], 56–79 years) for Finnish-born and 30 years (IQR
23–40 years, p < 0,001) for foreign-born cases.
Characteristics and incidence of recurrent TB
After a careful review of the 84 cases with more than one
episode registered, 50 TB cases (0.6% of all cases in the
cohort) were classified as recurrent (Fig. 1). The mean
overall incidence of recurrence was 112.9 (95% confidence
interval [CI], 85.6–148.9); for the first year of follow-up
the overall incidence was 236.4 (95%CI 140.0–399.2) and
for the second year of follow-up 206.7 (95%CI 114.5–
373.2) per 100,000 person-years. Out of the 50 recurrent
cases, two had three disease episodes and 48 two disease
episodes. Forty cases were culture positive in all episodes.
The median age was 51.5 years (range 6–95 years) at the
registration of the first episode; eleven cases (22%) were
female. In the first episode 44 cases (88%) and in the sec-
ond episode 39 cases (78%) were classified as pulmonary
TB. Two cases were HIV positive; for 64% of cases HIV
had not been tested. Nine recurrent cases (18%) were of
foreign origin. A history of substance abuse, mostly alco-
hol, was registered in the patient records in at least 1 TB
episode of 59% of males and none of females; 49% of
males had substance abuse recorded in both episodes.
Management of the TB episodes preceding recurrence
Among the 48 recurrent cases (96%) with complete patient
records, 36 cases (75%) received standard treatment in the
first episode (Table 2). Among these, the duration of
Fig. 1 Steps in identifying recurrent cases of tuberculosis, Finland, 1995–2013. a Non-tuberculous mycobacterium registered as M. tuberculosis
(N = 2), registration for false identity (N = 1) or incorrect registration date by the notifier (N = 10). b Only one long continuous TB episode (N = 5),
or treating physician decided to give TB treatment without specific evidence of TB and in subsequent expert assessment by the study team there
was another more likely cause for the disease (N = 9)
Table 1 Distribution of demographic and potential risk factors
for recurrent tuberculosis in a national TB cohort of 8084 cases,
Finland 1995–2013
Variable TB recurrence
(n = 50)
No TB recurrence
(n = 8034)
All (n = 8084)
Median age, years 51, 5 66 66
Gender female n (%) 11 (22%) 3457 (43%) 3468 (42.9%)
Foreign origin n (%) 9 (18%) 1066 (13.6%)a 1074 (13.6%)b
Pulmonary site of disease
n (%)
44 (88%)c 5599 (69.2%) 5605 (69.3%)
Culture positive n (%) 48 (96%)c 6631 (82.5%) 6680 (82.6%)
Prior to year 2007 n (%) 45 (90%)c 5762 (71.7%) 5807 (71.8%)
a Origin known for 7862 cases
b Origin known for 7912 cases
c Data of the first episode
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treatment was short (<5.5 months) in six cases, and the in-
tensive phase (<54 days) in three cases. Twelve cases (25%)
received non-standard treatment due to drug resistance,
adverse effects, or the treating physician’s decision. Of
these, six cases received TB treatment regimens that were
assessed as probably effective, one of them for a too short
time period. Treatment regimens of six cases were assessed
as probably ineffective. Six cases (12.5%) received directly
observed therapy (DOT). Among the 49 cases with treat-
ment outcome, it was successful in 27 cases (55.1%). In 12
cases (24.5%) the treating physician had stopped the treat-
ment prematurely, and in two cases (4.1%) interruption was
due to the patient. Eight cases (16.3%) were still on treat-
ment at 12 months (all finally completed treatment).
There were no recurrent cases with an MDR isolate in
either episode. Five cases were initially infected with
isoniazid-resistant isolates, but in three of these cases,
the treatment regimen was not modified accordingly. In
two cases, additional resistance to streptomycin and in
one case resistance to pyrazinamide developed during
treatment. In one case, initially fully susceptible isolate
developed resistance to pyrazinamide.
Risk factors for recurrence in the national cohort
The median follow-up time of cases in the cohort of
8084 TB cases was 6.1 years (IQR 2.7–11.1 years). The
recurrence occurred within less than 2 years in 25 (50%),
two to less than 4 years in 8 (16%), and later in 17 cases
(34%) (Fig. 2a). No recurrences occurred in females and
for extrapulmonary cases after the first 2 years (Fig. 2b
and c). In univariate analysis of variables available for
the national cohort, the cumulative risks of recurrence
between males and females, and between pulmonary and
extrapulmonary TB did not differ statistically
significantly at 1 and 2 years of follow-up (Table 3).
However, at 18 years of follow-up, the cumulative risk
for males was nearly fourfold compared to females
(Fig. 2b), and more than fivefold for pulmonary TB com-
pared to extrapulmonary TB (Fig. 2c). The risk of recur-
rence decreased with every additional 10 years of age
(Table 3). When only cases that were culture positive in
all episodes were included, the recurrence rate was simi-
lar to that seen in the whole recurrent cases cohort
(Fig. 2d). Whether the first episode occurred prior to
versus after 2007 did not have a significant association
with the risk of recurrence (Table 3).
In the multivariate analysis (Table 3) younger age
remained an independent risk factor for cumulative risk
of recurrence at all time points, and male gender and
pulmonary TB at 18 years of follow-up.
Discussion
We investigated the epidemiology and the prevalence of
risk factors associated with recurrence of TB in Finland
in a comprehensive national, register-based cohort of
8084 TB cases from 1995 to 2013, and found in a
follow-up of up to 18 years that 0.6% of cases during the
study period were recurrent. The overall incidence of
recurrence is 10–20 times higher, and for the first 2
years of follow-up 20–40 times higher than the inci-
dence of TB in the general population in Finland during
the study period [7]. Patient chart review of the recur-
rent cases revealed that in nearly one fourth of the
recurrent cases, the physician had discontinued the
treatment of the first episode prematurely.
In register-based studies on recurrent TB, validation of
the data requires considerable effort to ensure data
Table 2 Distribution of treatment regimens in the first episodes of 50 TB cases with a recurrence
Treatment group Total in group Intensive phase
short
Intensive phase
adequate
Duration of treatment
short
Duration of treatment
adequate
Standard treatment Aa 15 NA 15 1 14
Standard treatment Bb 4 NA 4 2 2
Standard treatment with short intensive
phase Cc
3 3 NA 2 1
Standard treatment Dd 14 0 14 1 13
Other probably effective combination of
anti-TB drugse
6 NA NA 1 5
Other probably ineffective combination of
anti-TB drugsf
6 NA NA NA NA
Not evaluated 2 – – – –
NA not applicable, H isoniazid, R Rifampicin, Z pyrazinamide, E ethambutol
a HRZ in intensive phase, HR in continuation phase, adequate duration of treatment ≥ 5.5 months
b HRE in intensive phase, HR in continuation phase, adequate duration of treatment ≥ 8 months
c Short intensive phase <54 days in standard treatment A or B
d ≥ 4 anti-TB drugs, including HRZ (adequate duration of treatment ≥ 5.5 months) or HRE (adequate duration of treatment ≥ 8 months)
e Non-standard combinations guided by drug resistance or due to adverse effects, the adequacy of treatment duration assessed by the study group
f Drug resistance ignored or inappropriate dosing
References [9, 12, 13]
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quality, as demonstrated in our study using a register with
proven high sensitivity and specificity for TB [17], after
which automated notification from the laboratories and
mandatory reminders from the laboratory to the clinician
on the need to notify were introduced. We observed that
out of the 84 cases initially identified in the register data
as recurrent, only 50 cases were truly recurrent. Major
reasons for inaccuracies in our register data included
incorrect notification dates, and notifying clinical TB cases
without microbiological confirmation, which the chart
review revealed to be incorrect. Without validation of the
data for recurrent TB cases, the proportion of recurrent
  a   b
  c   d
Fig. 2 Cumulative risk of recurrence of TB by follow-up time (and its pointwise 95% confidence limits). a Overall cohort; (b) By gender; (c) By
anatomical site of disease; (d) Only culture positive TB
Table 3 Univariate and multivariate analysis for risk factors of TB recurrence in a national cohort of TB cases in Finland, 1995–2013
Variables Univariate RR 95% CI p Multivariate RR 95% CI p
Males at 1 year a 1,43 0,48–4,26 0,52 1,93 0,40–9,31 0,41
Males at 2 years a 1,18 0,53–2,62 0,69 1,39 0,44–4,38 0,58
Males at 18 years a 3,92 1,95–7,91 < 0,001 5,88 2,21–15,66 < 0,001
Pulmonary TB at 1 year b 1,72 0,48–6,19 0,40 4,13 0,58–29,67 0,16
Pulmonary TB at 2 years b 1,87 0,70–4,99 0,21 2,00 0,43–9,33 0,38
Pulmonary TB at 18 years b 5,54 2,17–14,14 < 0,001 15,15 4,98–46,08 < 0,001
Age + 10 years 0,87 0,77–0,98 0,03 0,83 0,70–0,99 0,04
Finnish origin 0,64 0,31–1,33 0,23 – – –
1.episode before 2007 1,33 0,81–2,21 0,26 – – –
a Reference females. Overall p-value for male gender in univariate analysis < 0,0001 and in multivariate analysis 0,0015
b Reference extrapulmonary TB. Overall p-value for pulmonary TB < 0,0001
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cases out of the total cohort in our study would have been
almost double, stressing the need for rigid patient chart
review when assessing TB recurrence.
Over 80% of recurrent cases in Finland are relapses of
the previous infection [8], as elsewhere in low-incidence
countries [3, 18, 19]. In register-based investigations of
recurrent TB in low incidence-countries, careful review
of the actual treatment in the first TB period of recur-
rent cases has rarely been reported [20, 21]. We
observed that approximately two thirds, including those
who received treatment lasting over 12 months, had
received an adequate treatment. Just over one half
among the recurrent cases had in the first episode a
successful outcome according to WHO criteria [11].
Important for training policy was the finding that clearly
more frequently than interruption due to the patient,
the treating physician had discontinued treatment pre-
maturely, as described in our previous report [12]. Inad-
equate treatments were caused by the presence of drug
resistance without appropriate treatment regimen modi-
fication, absence of appropriate extension of duration of
treatment when treatment was modified, adverse effects,
or the physician’s decision to stop without the reason
being documented in the patient record.
The overall incidence of recurrence in the national
cohort, with a median follow-up period of 6 years,
and up to 18 years, was 113/100000, 10–20 times
higher than for the general population in Finland, in
line with long-term follow-up in low-incidence coun-
tries (71–410/100000) [3, 16]. For the first year of
follow-up, starting at 12 months from the registration
of the first episode, the incidence of recurrence was
236/100000, of the same magnitude as in recent
studies from Australia [3] and Denmark [18], but
clearly lower than in a number of earlier studies from
industrialised countries [22].
Our observation in the national cohort of male gender
as a risk factor for recurrence is in line with some previous
reports from low-incidence countries [23–25], but this
finding has been inconsistent [20, 21]. Substance abuse
data is not collected in the NIDR for the national cohort,
but we found in nearly 60% of the recurrent male cases a
history of substance abuse in patient charts, but none in
females, which could contribute to the excess risk seen in
males. An association between treatment adherence and
alcoholism has been reported in recurrent TB in the USA
[20]. We found in the national cohort the risk of recur-
rence higher for pulmonary than for extrapulmonary TB,
in line with earlier studies [16, 23, 26]. More than 40% of
our recurrent cases (data not shown) had both pulmonary
and extrapulmonary infection in the first episode, which
has been reported to be a risk factor for recurrences [25].
An unexpected finding in the national cohort was that the
risk of recurrence was associated with younger age,
whereas in two earlier studies, age > 65 years [20] or age
between 25 and 64 years [23] have been reported as risk
factors for recurrence. In earlier studies, either being an
immigrant [16, 20, 25] or being borne in the country [21]
were reported as risk factors, while origin was not a risk
factor for recurrence in our national cohort study.
Limitations of our cohort study include the fact that we
may fail to identify some recurrences, as recurrences
before 360 days from the date of the initial episode (early
recurrences) were not analysed from the register data. The
standard cut-off time recommended by WHO, at which
treatment outcome is recorded, is 12 months [11]. There-
fore, we chose this timepoint as a cut-off for recurrence,
in line with eg a large UK cohort [16]. The proportion of
early recurrences in retrospective studies is small [3, 18].
In addition, in retrospective studies, it may be difficult to
distinguish between treatment failures and early recur-
rences as sputum samples are not systematically collected
during treatment, and in our study we also included
culture negative and extrapulmonary cases. Almost one
third of our recurrent cases do not meet the WHO treat-
ment regimen description and outcome criteria for a
recurrent case [11]. However, the careful validation
process of our register data demonstrates that the same
challenges are likely to be present in other register-based
studies, unless careful validation has been performed. As a
country with very low incidence for HIV [7], the absence
of systematic testing of all TB cases for HIV is unlikely to
introduce a bias in the risk analysis.
The observations on the shortcomings of treatment
among the first episodes of the recurrent cases are
important for guiding training and system development
for the integrated TB control program. In 2013–2015,
treatment outcome in Finland was successful (cure or
completed treatment) in 75–78% of pulmonary TB cases
[7], as in the European Region on average [27].
Conclusions
In the absence of a comprehensive DOT strategy, the rate
of TB recurrence was found to be low in Finland. An
important finding was that in one fourth of the recurrent
cases, the physician had discontinued the treatment pre-
maturely, which implies that training of physicians needs
to be improved and, as TB becomes rare, treatment
should possibly be provided in fewer centers. The first 2
years after a TB episode is a very high-risk period for
recurrence: this could be incorporated as an automated
high-risk signal in the developing integrated electronic
patient management systems for reducing the delays in
implementing TB diagnostics and treatment.
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Abstract
Recurrent tuberculosis (TB) is caused by an endogenous re-activation of the same strain of Mycobacterium tuberculosis (relapse) or exogenous
infection with a new strain (re-infection). Recurrence of TB in Finland was analysed in a population-based, 19-year study, and genotyping was
used to define relapse and re-infection. The M. tuberculosis isolates from patients with suspected relapse were further analysed by whole
genome sequencing (WGS) to determine the number and type of mutations occurring in the bacterial genome between the first and
second disease episodes. In addition, publicly available tools (PHYRESSE and SPOLPRED) were used to predict drug resistance and
spoligotype profile from the WGS data. Of the 8299 notified TB cases, 48 (0.6%) patients had episodes classified as recurrent. Forty-two
patients had more than one culture-confirmed TB episode, and isolates from two episodes in 21 patients were available for genotyping.
In 18 patients, the M. tuberculosis isolates obtained from the first and second TB episodes had identical spoligotypes. The WGS analysis of
the 36 M. tuberculosis isolates from the 18 suspected relapse patients (average time between isolates 2.8 years) revealed 0 to 38 single
nucleotide polymorphisms (median 1, mean 3.78) between the first and second isolate. There seemed to be no direct relation between
the number of years between the two isolates, or treatment outcome, and the number of single nucleotide polymorphisms. The results
suggest that the mutation rate may depend on multiple host-, strain- and treatment-related factors.
© 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Introduction
Tuberculosis (TB) remains a major global health problem with 9
million new TB cases notified worldwide in 2013. TB ranks as
the second leading cause of death from an infectious disease
with an estimated 1.5 million TB deaths in 2013 [1]. Recurrent
TB is defined as an episode of TB occurring in the same person
after successful treatment [2–4]. Two processes can cause
recurrence: endogenous re-activation with the same strain of
Mycobacterium tuberculosis (relapse) or exogenous infection
with a new strain (re-infection). Recurrent TB episodes, of
which 0.3 million were reported in 2013, contribute consid-
erably to the burden of TB [1]. Recurrent TB has been re-
ported to occur in 0%–14% of patients after successful
treatment over 1–3 years of follow up [5]; in low-incidence
countries, rates of recurrence have varied between 0.4% and
7% [4–6].
Genotyping methods can be used to aid in the differen-
tiation between relapse and re-infection. As M. tuberculosis
isolates from both disease episodes need to be analysed
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with the same molecular marker, results are available from
only a few studies. Studies have shown that in recurrent TB
the proportion of disease due to re-infection varies from 4%
[5] to >60% [6,7]. A high proportion of apparent re-
infections may be due to mislabelling, cross-contamination,
mixed infections (the presence of more than one strain),
or to differences in patient populations, length of follow up,
and background risk of infection with M. tuberculosis [8].
Recently, whole genome sequencing (WGS) has proved to
be useful and more discriminatory than standard genotyping
for the distinction of re-infection and relapse [8,9]. As dif-
ferentiation between relapse and re-infection is crucial in
terms of patient treatment and public health response, a
discriminatory method could aid in this challenging
differentiation.
Finland has been a low-TB-incidence country since 2001. In
2013, 271 new TB cases were notified and TB incidence was 5/
100 000. Although the majority of cases are still detected
among elderly, native Finns, the number and proportion of
immigrant cases is increasing. In 2013, 17 (6%) of the newly
notified TB cases were reported to have had a previous episode
of TB since 1950. In 2013, a favourable outcome of treatment
(cure or completed treatment) was achieved in only 68% of
pulmonary TB cases in Finland, and 16% of TB patients died
before or during TB treatment [10].
The aim of the study was to analyse how many recurrent TB
cases were diagnosed in Finland during the years 1995–2013,
and to define, by using molecular methods, how many of the
cases were caused by relapse versus re-infection. The
M. tuberculosis isolates from relapse cases were further analysed
by WGS to determine the number and type of mutations
occurring in the bacterial genome between the first and second
disease episodes. In addition, publicly available tools were used
to predict drug resistance and spoligotype profile from the
WGS data.
Materials and methods
Clinical microbiology laboratories notify new M. tuberculosis
isolations directly to the National Infectious Disease Register
and submit isolates to the Mycobacterial Reference Laboratory
at National Institute for Health and Welfare (THL) for drug
susceptibility testing (ethambutol, isoniazid, pyrazinamide,
rifampicin, streptomycin) and genotyping. In addition, physicians
notify clinically suspected or confirmed TB cases. Data from the
different sources were linked as a case by the unique person-
identifying number used in all Finnish healthcare systems.
Data on country of origin were retrieved from the national
population registry.
Recurrent TB was defined as a case with a registration date
of a new TB episode in the same patient >360 days after the
registration date of a first episode, irrespective of the treatment
and treatment outcome in the initial episode. For the present
report, all episodes of TB had to be culture confirmed and
occur during 1995–2013. The registration date in culture-
positive cases is the sampling date of the first culture that
was positive for M. tuberculosis. Based on reviewing laboratory
data and patient charts of all initially identified recurrent epi-
sodes, known laboratory contaminations and registration er-
rors (non-tuberculous mycobacterium registered as
M. tuberculosis or registration for false identity or false date)
were excluded, as well as cases in which there was only one
definite TB episode. Treatment outcome for the first episode
was defined according to WHO criteria [1]. Treatment
outcome was classified as successful, if treatment outcome was
‘cured’ or ‘completed treatment’ at 12 months; unsuccessful, if
treatment outcome was ‘died, failed, or lost to follow up’; or
not known, if treatment outcome was not evaluated.
Clinical specimens, obtained from persons suspected of
having TB, were decontaminated and cultured in a BACTEC
MGIT TB system (Becton Dickinson, Franklin Lakes, NJ, USA)
following standard procedures. The isolates were re-grown on
Löwenstein– Jensen medium to obtain a pure culture for gen-
otyping and were characterized by spoligotyping [11]. After
initial genotyping, isolates were stored frozen (–20°C) and
were re-cultured on 7H11 agar plates for WGS analysis.
Whether M. tuberculosis isolates from both disease episodes
were available for analysis, depended on the time of the disease
episode. Before the year 2000, only every tenth M. tuberculosis
isolate was stored in the culture collection.
Genomic DNA was isolated using a DNeasy blood and
Tissue kit (Qiagen, Hilden, Germany) and paired-end multiplex
libraries were prepared with a Nextera XT kit (Illumina, San
Diego, CA, USA) at the Bacterial Infections Unit of the National
Institute for Health and Welfare (Turku, Finland). The libraries
were sequenced at the Finnish Microarray and Sequencing
Centre (Turku, Finland) using the MiSeq platform (Illumina)
according to the manufacturer’s recommendations. Sequence
reads were processed as described previously [12]. The average
coverage of the reference genome (percentage bases >15) was
95.2% (range 71.8%–99.3%). SNPs were considered valid if
supported by at least two and >70% of mapped reads on each
strand with a minimum mapping quality of 45. Single nucleotide
polymorphisms (SNPs) in annotated repeat regions and other
notoriously difficult to map regions, comprising 9.3% of the
genome, were excluded from further analysis. Variant sites that
passed quality filters in all isolates were extracted using custom
scripts [12] and used to determine SNP distances between
isolates.
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Sequences were analysed using the PHYRESSE and MYKROBE
online tools (v. 0.2.1) for detection of drug-resistance-
conferring mutations (27 October 2015). Spoligotypes were
predicted from the WGS data using the SPOLPRED tool (down-
loaded in July 2015) [13–15].
The ethics approval for the study was given by the Ethics
Committee of Tampere University Hospital, Tampere, Finland.
Results
A total of 8299 TB cases were notified in Finland during
1995–2013. Analysis of the national TB registry data identified
63 patients, for whom more than one TB episode had been
registered. After careful review of all laboratory data and pa-
tient charts, 48 TB cases were classified as being recurrent
(0.6% of all registered cases) (Fig. 1). Of the 42 patients with
more than one culture-confirmed TB episode, for 21 patients
isolates from repeat episodes were available for genotyping.
In 18 of the 21 (86%) patients, the M. tuberculosis isolates
obtained from first and second TB episodes had identical spo-
ligotypes and were suspected of having relapse TB (Table 1).
The average age of the patients was 62.8 years (range
25–95 years) at the time of the registration of the first TB
episode, 13 were men and five were women. The country of
origin was Finland for 15 patients, and Cameroon, Russia and
Somalia, each for one patient. The average period between the
registration dates of the first and second TB episodes was
2.8 years (range 1.0–9.8 episodes). The relapse occurred in the
first 2 years from the registration date of the first episode in
nine cases (50%), between 2 and 4 years in seven cases (39%),
and after >4 years in two cases (11%). The first TB disease
episode was pulmonary in 13 cases and extrapulmonary in five
cases. One case was confirmed to be in an HIV-positive patient.
Treatment outcome of the first episode was classified as suc-
cessful (completed treatment) in ten cases (56%), unsuccessful
(lost to follow up) in four cases (22%), and not known in four
cases (22%). The second episode was pulmonary in 12 cases,
extrapulmonary in four cases, and both in two cases.
The 36 M. tuberculosis isolates obtained from the consecutive
episodes of the 18 patients with suspected relapse were sub-
mitted for WGS. The number of SNPs between the first and
second isolates varied from 0 to 38 (median 1, mean 3.78). In
the majority of pairs (17 of 18) the number of SNPs was be-
tween 0 and 6 (median 1, mean 1.76), strongly suggesting that it
was a relapse case. However, in one pair the SNP difference
was 38, developed in a 2.2-year time between the isolation
dates, leaving the interpretation unclear. The number of mu-
tations per genome per year ranged from 0 to 17.3 for all
isolates, the average being 1.37. When excluding the outlier, the
average number of mutations per genome per year was 0.63.
There seemed to be no direct relation between the number of
years between the two isolates, or treatment outcome, and the
number of SNPs (Fig. 2). The genomic location and type of
360 days between repeat episode registra on dates (63) 
Laboratory contamina on or error in 
registra on (5) 
Recurrent cases (48) 
Chart review: only one TB episode (10)  
More than one culture posi ve TB episodes (42) Only one culture-posi ve TB episode (6) 
Isolates from two episodes available (21)  
Spoligotyping 
Isolates from one 
episode only (21) 
Relapse (18)  
WGS 
Re-infec on (3) 
Registered TB cases 1995–2013 (8299) 
FIG. 1. Steps in identifying recurrent
cases of tuberculosis, Finland,
1995–2013.
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mutation for each SNP detected is listed in the Supplementary
material (Table S1).
In predicting spoligotype from WGS data by SPOLPRED, the
results were identical for 28 isolates and discordant for eight
isolates. The eight discordant spoligotype profiles all had the
same misclassification, an exact match to spacer 31 was
detected by SPOLPRED, but not by blotting. However, spacer 31
was detected in 14 other isolates by both blotting and SPOLPRED.
Rechecking of the original spoligotype blots did not resolve the
discrepancy. Recurrent isolates belonged to Haarlem (n = 11,
61%), T (n = 5, 28%), LAM (n = 4, 22%), and Ural (n = 1, 6%)
lineages. The distribution of spoligotype lineages was similar to
what has been observed for M. tuberculosis isolates in Finland
previously [11].
Based on conventional drug susceptibility testing, three pa-
tients were infected with drug-resistant isolates. Isolates from
one patient were resistant to isoniazid (first episode) and
isoniazid combined with streptomycin (second episode), and
isolates from the second patient were resistant to isoniazid
alone (both episodes). In the third patient, the isolate from the
second episode was resistant to pyrazinamide by the pheno-
typic method. This was confirmed by PHYRESSE analysis.
Moreover, the isolate from the first episode of the same patient
was found to carry the same high-probability pyrazinamide
resistance mutation encoding a His51Gln amino acid change in
the PncA. However, the pyrazinamide resistance mutations
could not be confirmed with the MYKROBE tool (23 November
2015). Additional mutations indicating resistance were not
detected from the WGS data.
Discussion
Recurrent TB, and particularly relapsed cases can be seen as a
proxy for the quality of the national TB programme [16]. To
our knowledge, this is the first population-based study in a low-
TB-incidence country that used WGS for the investigation of
recurrent TB. The overall rate of recurrence (0.6%) detected
during our 19-year study period is in line with other low-TB-
incidence countries [4,17,18], even if not standardized for the
duration of follow up.
The difference in SNPs between the majority of the
consecutive isolates in relapse cases observed in our study (0 to
6) was comparable to a study from Malawi finding the number
of SNPs between 0 and 8 [8]. In another study from three high-
incidence countries, the average number of mutations observed
among relapse cases was 0.47 SNPs [9], which is lower than
was found in our study (1.76 SNPs). This is most likely a result
of the shorter time period between the two isolates used in
their study (17–60 weeks) compared with ours
(1.0–9.8 years). However, we found no direct relation between
the number of years and number of SNPs in isolates from the
same patient. This suggests that there is no steady mutation rate
per year but the rate is probably dependent on factors such as
patient characteristics, treatment regimen, treatment compli-
ance, strain lineage or type. Due to the small number of relapse
cases observed in Finland, it was not possible to assess statis-
tically the correlation between the time and SNPs observed in
relapse isolates.
TABLE 1. Demographic, clinical, drug treatment and genotyping characteristics of 18 cases of relapsed tuberculosis, Finland,
1995–2013
Nr Age Gender
Country
of birth
First episode Second episode
Spoligotype
SNPs between
isolatesDisease
Drug
resistancea
Treatment
outcomeb
Drug
resistance
Year
differencec
1 70 Male Finland Pulmonary INH Unsuccessful INH+SM 2 SIT47 0
2 71 Male Finland Pulmonary and other (pleura) No Successful No 2.2 SIT46 38
3 95 Female Finland Other (lymph node) No Not known No 1 SIT53 5
4 52 Male Finland Pulmonary No Successful No 7.2 SIT49 1
5 47 Male Finland Pulmonary and other (pleura) No Unsuccessful No 1.1 SIT262 5
6 78 Female Finland Pulmonary and other (pleura) INH Not known INH 2.9 SIT917 2
7 40 Male Finland Pulmonary and other (pleura) No Successful No 8.9 SIT50 4
8 64 Male Finland Pulmonary No Successful No 3.8 SIT56 0
9 81 Female Russia Other (uterus) No Unsuccessful No 1.8 SIT20 1
10 72 Female Finland Pulmonary No Successful No 2.9 SIT53 3
11 70 Male Finland Pulmonary No Unsuccessful No 1.6 SIT47 0
12 48 Male Finland Pulmonary No Not known No 3.1 SIT383 1
13 78 Male Finland Other (pleura) No Successful No 1.9 SIT871 0
14 87 Male Finland Other (bone & joint) No Not known No 2.5 SIT50 6
15 25 Male Cameroon Pulmonary No Successful No 1.6 SIT20 2
16 68 Male Finland Pulmonary No Successful PZA 1.2 F343 0
17 25 Female Somalia Other (lymph node) No Successful No 2.8 F427 0
18 45 Male Finland Pulmonary No Successful No 1.2 SIT42 0
aAntibiotic abbreviations: INH, isoniazid; SM, streptomycin; PZA, pyrazinamide.
bTreatment outcome classified according to the WHO standard.
cIndicates the time difference between the sampling dates of the first positive M. tuberculosis culture in the first and second disease episode.
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In most cases, TB relapse versus re-infection was distinctly
defined by bothWGS and spoligotyping. However, in those cases
where the second disease episode was caused by an
M. tuberculosis isolate that is dominant in the Finnish population
(such as SIT53 or SIT47), re-infection cannot be definitely ruled
out. In one case, the difference between the two M. tuberculosis
isolates was 38 SNPs, although both episodes occurred within
2 years. This difference exceeds the average number of SNPs
detected in this and other studies comparing consecutive isolates
of the same patient or in a transmission chain (0–10 SNPs)
[9,12,19,20]. Based on medical records, appropriate treatment
was prescribed for this patient, but compliance was poor, and the
patient received high-dose corticosteroids for several months
during TB treatment, which may have made the patient more
susceptible to M. tuberculosis relapse or re-infection. The
M. tuberculosis isolate of the first disease episode (H0901/98) had
20 unique SNPs and the second isolate (H1015/00) had 18 unique
SNPs compared with reference sequence (M. tuberculosis
H37Rv). This suggests that the second isolate did not evolve
directly from the first, making the relapse theory less likely. This
patient developed a third culture-positive disease episode 3 years
after the second episode, but unfortunately, no isolate was
available for analysis from the third episode.
As WGS is likely to become the standard for typing of
M. tuberculosis isolates in the near future, it is important tomaintain
comparability with data obtained with previously used genotyping
methods, such as spoligotyping.When the SPOLPRED tool was used
to predict spoligotype profiles from sequences, results were
identical except for one spacer. Further studies are needed to
assess whether this is a systematic error either in theWGS analysis
tool or in the interpretation of the traditional spoligotype blots.
Two publicly available online tools, PHYRESSE and MYKROBE,
were used to search drug-resistance-related mutations from
WGS data. However, only the mutation conferring resistance to
pyrazinamide was identified with the PHYRESSE tool, whereas
neither tool was able to detect drug-resistance-conferring mu-
tations in any of the four isolates phenotypically resistant to
streptomycin or isoniazid. This may be a result of resistance
caused by previously unknown mutations, incorrect interpreta-
tion of the phenotypic assays, or low coverage of the sequence
data. However, the latter was checked and, according to PHYR-
ESSE, 100% coverage for all regions known to be associated with
drug resistance was obtained for all of the 36 isolates.
To conclude, in our population-based study spanning 19 years
of national surveillance on recurrent TB cases, WGS seemed to
concur well with spoligotyping in discriminating between relapse
and re-infection in a low-incidence country. The results suggest
that there is no steady mutation rate per year but it may depend
on multiple host-, strain- and treatment-related factors.
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